Data / Research funding / Pneumonia
Pneumonia: 599 NIH awards ($644.9M) to 179 organizations
599 NIH awards ($644.9M) in the NIH spending category Pneumonia, to 179 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 599 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Coordination for ARDS, Pneumonia, and Sepsis supporting Training, Organization and Network Efficiency (CAPSTONE) | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $16,153,090 | May 1, 2023 | April 30, 2029 | SELF, WESLEY H | reporter.nih.gov |
| Successful Clinical Response In Pneumonia Therapy (SCRIPT) Systems Biology Center | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,773,513 | January 17, 2018 | December 31, 2027 | WUNDERINK, RICHARD G | reporter.nih.gov |
| Disordered Proteostasis as a Driver of Disease in the Aging Lung | NIH | National Institute on Aging | 2021 to 2024 | $8,161,610 | July 1, 2015 | March 31, 2025 | BUDINGER, GR SCOTT | reporter.nih.gov |
| Adjuvant Development of the TLR4 Ligand BECC470s For Use in Influenza, S. aureus, and P. aeruginosa Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $7,143,498 | September 30, 2023 | September 29, 2028 | SORENSON, GREGORY | reporter.nih.gov |
| Developing Teixobactin for Respiratory Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,154,703 | March 22, 2021 | February 28, 2027 | HUGHES, DALLAS | reporter.nih.gov |
| 1/1: ARREST RESPIRATORY FAILURE DUE TO PNEUMONIA (ARREST PNEUMONIA) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $5,715,477 | September 23, 2019 | August 31, 2025 | LEVITT, JOSEPH ERIC | reporter.nih.gov |
| Inducible epithelial resistance: a program investigating mechanisms to protect against acute and chronic complications of pneumonia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,382,400 | March 5, 2019 | February 28, 2026 | EVANS, SCOTT E. | reporter.nih.gov |
| Preclinical Pulmonary Fibrosis, an opportune rare disease cohort | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $4,290,758 | August 20, 2020 | July 31, 2026 | SCHWARTZ, DAVID ALBERT | reporter.nih.gov |
| Derivation and Validation of the Pediatric Community-Acquired Pneumonia Severity (PedCAPS) Score | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $3,862,565 | February 1, 2023 | January 31, 2028 | FLORIN, TODD ADAM | reporter.nih.gov |
| Inborn errors of immunity in patients with life-threatening COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,707,765 | July 12, 2021 | June 30, 2026 | CASANOVA, JEAN-LAURENT | reporter.nih.gov |
| THE ROLE OF THE NON-CANONICAL INFLAMMASOME IN INNATE IMMUNITY | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,707,189 | June 11, 2021 | May 31, 2027 | AMER, AMAL O | reporter.nih.gov |
| Programming of PMN host-defense function during transendothelial migration | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,648,697 | June 11, 1993 | June 30, 2027 | KOMAROVA, YULIA A | reporter.nih.gov |
| Development of ureadepsipetides for drug-resistant infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,597,406 | December 17, 2018 | November 30, 2024 | LAFLEUR, MICHAEL | reporter.nih.gov |
| CD4_T-cell_Immunity_in_the_Lung | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,557,478 | February 1, 2018 | January 31, 2025 | KOLLS, JAY K | reporter.nih.gov |
| Novel mechanisms regulating immunity to respiratory virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,546,288 | August 2, 2023 | July 31, 2027 | PAUST, SILKE | reporter.nih.gov |
| Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,483,730 | September 1, 2023 | August 31, 2028 | ROSEN, DAVID A. | reporter.nih.gov |
| Novel bi-specific immunotherapeutic against high-threat Gram-negative pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,410,042 | February 21, 2019 | January 31, 2025 | PERLIN, DAVID S | reporter.nih.gov |
| Development of Gene-Silencing Therapeutics for Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,379,247 | August 1, 2019 | July 31, 2025 | GREENBERG, DAVID ELIHU | reporter.nih.gov |
| Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,343,171 | January 9, 2019 | December 31, 2024 | IBRAHIM, ASHRAF S. | reporter.nih.gov |
| A Phase III Randomized Controlled Trial of Azithromycin for RSV-induced Respiratory Failure in Children | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $3,324,945 | August 1, 2021 | July 31, 2027 | KONG, MICHELE | reporter.nih.gov |
| The role of Chlamydia pneumoniae infection in Alzheimer's Disease | NIH | National Institute on Aging | 2021 to 2025 | $3,300,943 | September 30, 2021 | June 30, 2027 | CROTHER, TIMOTHY ROBERT | reporter.nih.gov |
| Pulmonary pathophysiology sub-phenotypes of pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,223,607 | February 1, 2022 | January 31, 2027 | MIZGERD, JOSEPH P | reporter.nih.gov |
| Uncovering associations of variant infection with COVID-19 disease severity in children | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $3,214,599 | January 1, 2021 | June 30, 2023 | CHIU, CHARLES YEN | reporter.nih.gov |
| Development of peptide nucleic acid antibiotics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,164,488 | February 10, 2021 | January 31, 2025 | ARYA, DEV PRIYA | reporter.nih.gov |
| Cardiovascular Risk, Vascular and Kidney Damage in COVID-19 Survivors | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,114,564 | January 20, 2022 | December 31, 2026 | CHIRINOS MEDINA, JULIO ALONSO | reporter.nih.gov |
| Immunological characterization of rationally-designed vaccines against plague in mice and non-human primate models | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,082,735 | February 1, 2021 | July 31, 2026 | CHOPRA, ASHOK K | reporter.nih.gov |
| Novel Strategies for Antibiotic Combinations to Combat Gram-negative Superbugs | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,081,358 | December 20, 2019 | November 30, 2025 | TSUJI, BRIAN | reporter.nih.gov |
| Novel delivery platform and antigen design for an effective COVID-19 vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,066,236 | August 11, 2020 | July 31, 2027 | MITTAL, SURESH K | reporter.nih.gov |
| Genetic Analysis of COVID-19 Susceptibility and Resistance Determinants in the Collaborative Cross | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,064,576 | September 25, 2020 | August 31, 2025 | HEISE, MARK T | reporter.nih.gov |
| Leveraging population-based human data to uncover mechanisms connecting Alzheimer's disease and common infections and facilitate vaccines repurposing for AD prevention | NIH | National Institute on Aging | 2021 to 2025 | $3,052,023 | September 30, 2021 | June 30, 2027 | OUKRAINTSEVA, SVETLANA V. | reporter.nih.gov |
| CoPARC: Colorado Pulmonary-Alcohol Research Collaborative | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $3,045,581 | August 1, 2011 | April 30, 2029 | BURNHAM, ELLEN L | reporter.nih.gov |
| Biomimetic Macrophage Membrane-Coated Nanosponges: A Novel Therapeutic for Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Hospital-Associated Pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,027,494 | July 1, 2023 | June 30, 2028 | NIZET, VICTOR | reporter.nih.gov |
| Evaluating darobactins as antimicrobial agents | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,000,880 | April 1, 2021 | March 31, 2026 | LEWIS, KIM | reporter.nih.gov |
| Optimization of orally bioavailable inhibitors for the treatment of COVID-19 and other human coronavirus infections | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,999,998 | June 7, 2023 | May 31, 2027 | COBURN, GLEN | reporter.nih.gov |
| Development of a Dual-Targeting ClpP Activating Antibiotic | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,999,619 | September 1, 2023 | August 31, 2026 | LAFLEUR, MICHAEL | reporter.nih.gov |
| Aminoglycosides with reduced ototoxicity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,999,400 | August 1, 2020 | February 28, 2026 | ARYA, DEV PRIYA | reporter.nih.gov |
| Prevention and Treatment of Pneumocystis Pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,969,486 | May 21, 2020 | April 30, 2026 | NORRIS, KAREN A | reporter.nih.gov |
| Novel G protein-based RSV vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,967,937 | August 1, 2020 | March 31, 2027 | LI, SHENGQIANG | reporter.nih.gov |
| Development of a broad spectrum teixobactin-lipopeptide hybrid for the treatment of lung infections caused by pan-drug resistant ‘superbugs’ | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,944,400 | June 21, 2022 | May 31, 2027 | RAO, GAURI G | reporter.nih.gov |
| Targeting abnormal alveolar immune activation and failed epithelial repair in COVID-19 | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,933,325 | April 1, 2022 | March 31, 2026 | MISHARIN, ALEXANDER | reporter.nih.gov |
| Dual drug delivery to lung/blood interface in respiratory infections. | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,888,500 | April 20, 2021 | March 31, 2025 | MUZYKANTOV, VLADIMIR R | reporter.nih.gov |
| Development of an RSV vaccine for the elderly | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,887,888 | March 2, 2020 | February 28, 2026 | MORRISON, TRUDY G. | reporter.nih.gov |
| Dissecting Yersinia Yop Targets in Neutrophils | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,883,504 | February 11, 2022 | January 31, 2027 | MECSAS, JOAN C | reporter.nih.gov |
| A New Class of Broad-Spectrum Antibacterial Agents to Treat Multi-Drug Resistant Pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,858,436 | July 21, 2023 | June 30, 2027 | SEBAHAR, PAUL | reporter.nih.gov |
| Betacoronaviruses: activation and antagonism of host innate immune responses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,828,524 | May 24, 2018 | April 30, 2028 | WEISS, SUSAN R | reporter.nih.gov |
| Molecular Determinants of Usual Interstitial Pneumonia (UIP) | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,826,957 | April 1, 2022 | March 31, 2027 | SCHWARTZ, DAVID ALBERT | reporter.nih.gov |
| Central role of Caspase-8 in control of host tolerance and resistance mechanisms in pulmonary macrophage populations during severe respiratory infections | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,808,365 | August 15, 2023 | May 31, 2027 | JAMIESON, AMANDA M | reporter.nih.gov |
| Mechanisms of regulatory T cell-mediated recovery from severe viral pneumonia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,783,450 | March 1, 2020 | June 30, 2029 | SINGER, BENJAMIN DAVID | reporter.nih.gov |
| Yersinia Outer-Membrane-Vesicle Vaccines Against Pneumonic Plague | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,776,243 | January 25, 2022 | December 31, 2026 | SUN, WEI | reporter.nih.gov |
| Child Lung Development Following a Cookstove Intervention: Evidence from GRAPHS | NIH | National Institute of Environmental Health Sciences | 2021 to 2025 | $2,763,681 | July 1, 2017 | February 29, 2028 | JACK, DARBY | reporter.nih.gov |
| Systems-based pharmacologic modelling to elucidate beta-lactam clinical pharmacodynamics and define optimal dosing regimens in severe pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,734,140 | July 11, 2022 | June 30, 2027 | RHODES, NATHANIEL JAMES | reporter.nih.gov |
| Sensing living P. aeruginosa using D-alanine derived radiotracers | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2024 | $2,693,051 | May 1, 2021 | January 31, 2026 | WILSON, DAVID M | reporter.nih.gov |
| Nosocomial pneumonias impair cognitive function | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,684,149 | April 1, 2018 | August 31, 2027 | LIN, MIKE | reporter.nih.gov |
| Amyloid-mediated cognitive dysfunction in bacterial pneumonia after TBI | NIH | National Institute on Aging | 2025 | $2,663,195 | September 15, 2025 | August 31, 2029 | WAGENER, BRANT M | reporter.nih.gov |
| Targeting Pneumococcal Transmission | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,658,920 | February 1, 2020 | January 31, 2026 | WEISER, JEFFREY NEAL | reporter.nih.gov |
| Macrorecombination in isolated cell pairs via natural genetic transformation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,657,698 | May 21, 2021 | April 30, 2027 | EDDINGTON, DAVID | reporter.nih.gov |
| Monoclonal Antibody to Combat Pseudomonas Aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,646,807 | August 15, 2023 | July 31, 2028 | GOLDBERG, JOANNA B | reporter.nih.gov |
| The interface between L. pneumophila manipulation of host endoplasmic reticulum and innate immune subterfuge | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,645,600 | February 20, 2020 | January 31, 2026 | ISBERG, RALPH R. | reporter.nih.gov |
| Mechanisms of Pneumococcal Persistence During Carriage | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,644,208 | April 1, 1996 | June 30, 2029 | WEISER, JEFFREY NEAL | reporter.nih.gov |
| Development of a Mucosal Nanoemulsion-Adjuvanted RSV Vaccine using Recombinant Pre-Fusion F Protein | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,617,783 | September 1, 2020 | December 31, 2025 | TRABBIC, KEVIN | reporter.nih.gov |
| GMP manufacturing and IND Filing of IN-002, a potent inhaled muco-trapping antibody therapy for Respiratory Syncytial Virus | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,605,456 | June 1, 2023 | May 31, 2027 | HUTCHINS, JEFF T | reporter.nih.gov |
| A multivalent O-antigen bioconjugate vaccine for the prevention of Klebsiella pneumoniae infections | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,591,387 | July 15, 2022 | July 31, 2027 | HARDING, CHRISTIAN | reporter.nih.gov |
| Innate Immune Clearance of Host-Adapted Pulmonary Pathogens | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,586,182 | January 11, 2017 | November 30, 2024 | PRINCE, ALICE S | reporter.nih.gov |
| Innate immune-mediated control of pulmonary Legionella pneumophila infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,572,725 | November 16, 2015 | June 30, 2027 | SHIN, SUNNY | reporter.nih.gov |
| Rapid, Breath Volatile Metabolite-Based Diagnosis, Species Identification, and Antibiotic Resistance Profiling in Bacterial Pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,571,160 | February 15, 2023 | January 31, 2028 | KOO, SOPHIA | reporter.nih.gov |
| Engineered “muco-trapping” antibodies for inhaled therapy of parainfluenza and human metapneumovirus infections | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,541,116 | September 19, 2022 | July 31, 2027 | LAI, SAMUEL | reporter.nih.gov |
| Pneumonia Biology | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,516,358 | January 11, 2017 | December 31, 2024 | MIZGERD, JOSEPH P | reporter.nih.gov |
| hHv1 channels in neutrophils and the innate immune inflammatory response | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,426,520 | August 5, 2022 | June 30, 2027 | GOLDSTEIN, STEVE A N | reporter.nih.gov |
| Targeting Estrogenic pathways in Tregs to promote ARDS resolution | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $2,413,250 | June 1, 2022 | May 31, 2026 | D'ALESSIO, FRANCO RAFAEL | reporter.nih.gov |
| Let-7b in Extracellular Vesicles Secreted by Bronchial Epithelial Cells Increases the Antibiotic Sensitivity of Pseudomonas | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,409,204 | December 15, 2020 | November 30, 2025 | STANTON, BRUCE A. | reporter.nih.gov |
| SBIR: In vivo validation and IND-enabling development of MM004, a bispecific inhaled immunotherapy for RSV and MPV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,380,033 | March 4, 2021 | February 28, 2026 | CONE, RICHARD | reporter.nih.gov |
| Fungal dysbiosis regulation of post-influenza bacterial pneumonia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,376,545 | July 16, 2021 | June 30, 2025 | CHEN, PETER | reporter.nih.gov |
| A prophylactic vaccine to prevent colonization by Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,345,744 | December 27, 2022 | November 30, 2027 | PICKING, WENDY L. | reporter.nih.gov |
| Cardiac microlesion formation during invasive pneumococcal disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,308,740 | November 1, 2014 | May 31, 2030 | ORIHUELA, CARLOS J | reporter.nih.gov |
| Evaluation of pregnancy on vaccine-induced immunity and protection in a pre-clinical model of RSV infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,306,179 | September 24, 2020 | August 31, 2025 | NORRIS, KAREN A | reporter.nih.gov |
| Follistatin-like 1 Mediated Host Defense in Bacterial Pneumonia | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,305,697 | July 1, 2022 | June 30, 2027 | CAMPFIELD, BRIAN T | reporter.nih.gov |
| IL-33 induced-lL-9 producing type 2 innate lymphoid cells in the regulation of acute lung injury after hematopoietic stem cell transplantation (HSCT) in pediatric patients | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,303,969 | January 1, 2022 | June 30, 2026 | PACZESNY, SOPHIE | reporter.nih.gov |
| Preclinical development of a synthetic lung surfactant dry powder aerosol for hypoxemia or acute respiratory distress syndrome patients receiving different modes of ventilation support | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,301,184 | July 1, 2023 | June 30, 2027 | LONGEST, P. WORTH | reporter.nih.gov |
| Deciphering the role of peroxisomes in bacterial pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,298,625 | September 19, 2022 | July 31, 2027 | O'CONNOR, TAMARA | reporter.nih.gov |
| Prevalence effects in visual search: Theoretical and practical implications | NIH | National Eye Institute | 2021 to 2025 | $2,283,459 | April 1, 2007 | June 30, 2029 | WOLFE, JEREMY M | reporter.nih.gov |
| LOX-1 as a protective countermeasure in response to lung infection | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,274,599 | June 15, 2023 | May 31, 2027 | QUINTON, LEE | reporter.nih.gov |
| Bioactivities of pneumococcal cell wall in neuropathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,255,100 | November 4, 2016 | January 31, 2027 | TUOMANEN, ELAINE I | reporter.nih.gov |
| Rapid, Breath Volatile Metabolite-Based Diagnostic for In Vivo Identification and Antibiotic Resistance Profiling of Bacterial Pathogens in Ventilator-Associated Pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $2,232,574 | June 20, 2018 | May 31, 2025 | KOO, SOPHIA | reporter.nih.gov |
| Mechanistic modeling of the innate immune responses of the human lung to understand the inter-individual heterogeneity of COVID-19 pneumonia | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,227,734 | July 1, 2023 | June 30, 2027 | MEHRAD, BORNA | reporter.nih.gov |
| Targeting RIPK3 in Flu-Associated Lung Injury | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,222,961 | September 18, 2019 | August 31, 2025 | BALACHANDRAN, SIDDHARTH | reporter.nih.gov |
| Coordinated regeneration of lung epithelial and endothelial compartments | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,201,693 | August 20, 2022 | July 31, 2026 | VAUGHAN, ANDREW | reporter.nih.gov |
| Novel mechanisms of Alveolar Macrophage-Dependent Antifungal Innate Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,192,702 | January 8, 2020 | December 31, 2025 | WRIGHT, TERRY W | reporter.nih.gov |
| Impact of inflammatory lipids on Yersinia pestis infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,171,406 | July 14, 2023 | June 30, 2027 | LAWRENZ, MATTHEW B | reporter.nih.gov |
| Developmental Exposures to Arsenic: Pneumonia, Immunity, and Microbiomes (DEAPIM) | NIH | National Institute of Environmental Health Sciences | 2023 to 2025 | $2,157,462 | February 5, 2022 | December 31, 2026 | PARVEZ, MUHAMMAD F | reporter.nih.gov |
| Novel bi-specific immunoprophylactics against multi-drug resistant Gram-negativebacterial infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,153,664 | March 22, 2019 | April 30, 2024 | PERLIN, DAVID S | reporter.nih.gov |
| Effective Primary care practices that Enhance Recovery Trajectories after pneumonia (EXPERT) | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,148,392 | September 15, 2023 | June 30, 2028 | IWASHYNA, THEODORE J | reporter.nih.gov |
| THE IMPACT OF ADVANCED AGE AND SEX ON HUMORAL IMMUNITY TO STREPTOCOCCUS PNEUMONIAE | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,121,108 | September 1, 2022 | August 31, 2027 | HAAS, KAREN M | reporter.nih.gov |
| Structure and Function of Legionella pneumophila Lysine Methyltransferases | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,118,862 | March 21, 2022 | February 28, 2027 | TRIEVEL, RAYMOND C | reporter.nih.gov |
| Macrophage-targeting Nanoplatforms as Immunotherapy against Pulmonary Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,117,352 | July 1, 2017 | November 30, 2028 | SAILOR, MICHAEL J | reporter.nih.gov |
| TRPV4 Regulates Mechanosensitive Macrophage Functions in Lung Injury | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,097,481 | February 1, 2021 | January 31, 2027 | SCHERAGA, RACHEL GREENBERG | reporter.nih.gov |
| Interleukin-27 in host response to Legionella infection | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,096,982 | July 1, 2023 | June 30, 2027 | BOSMANN, MARKUS | reporter.nih.gov |
| IDENTIFICATION AND CHARACTERIZATION OF T CELL EPITOPES FROM BACTERIAL PATHOGENS CAUSING PNEUMONIA | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,079,792 | September 30, 2025 | September 29, 2026 | PETERS, BJOERN | reporter.nih.gov |
| Transcriptional Regulation of Migrating Neutrophils during Pneumonia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,062,500 | July 1, 2021 | June 30, 2027 | TRABER, KATRINA | reporter.nih.gov |
| Pharmacokinetics analysis from first-in-human study of IN-002, a potent inhaled muco-trapping antibody therapy for RSV | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,049,871 | June 21, 2024 | May 31, 2027 | SCOTT, DAVID W | reporter.nih.gov |
| IND-enabling development for IN-003, an inhaled mAb therapy against human metapneumovirus infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,049,821 | May 15, 2024 | April 30, 2027 | HUTCHINS, JEFF T | reporter.nih.gov |
| Influenza A Inhibits TH17 Host Defense Against Bacterial Pneumonia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,049,603 | January 1, 2012 | March 31, 2026 | ALCORN, JOHN F | reporter.nih.gov |
| IND-enabling development for IN-002, an inhaled muco-trapping mAb against respiratory syncytial virus | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $2,042,193 | July 12, 2022 | June 30, 2024 | HUTCHINS, JEFF T | reporter.nih.gov |
| Molecular Insights into the Uropathogenesis of MDR Acinetobacter baumannii | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,021,352 | February 6, 2019 | January 31, 2025 | FELDMAN, MARIO | reporter.nih.gov |
| Cellular and molecular mechanisms of alveolar repair | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,019,414 | August 1, 2023 | May 31, 2027 | DESAI, TUSHAR JASUBHAI | reporter.nih.gov |
| Adjuvant Development of the TLR4 Ligand BECC470s For Use in Influenza, S. aureus, and P. aeruginosa Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $2,018,199 | September 30, 2023 | September 29, 2026 | SORENSON, GREGORY | reporter.nih.gov |
| Consequences of Direct Viral-Bacterial Interactions | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,014,549 | January 5, 2022 | December 31, 2026 | ROSCH, JASON W. | reporter.nih.gov |
| An immunodominance-based Pan-Pneumovirus vaccine for protection against RSV and hMPV | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,007,500 | June 6, 2023 | May 31, 2028 | MOUSA, JARROD | reporter.nih.gov |
| Pneumocystis: Macrophage & Epithelial Activation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,005,500 | July 10, 1993 | January 31, 2027 | LIMPER, ANDREW H | reporter.nih.gov |
| Preclinical development of an immunomodulatory agent capable of mitigating SARS-CoV-2 virus related hypercytokinemia | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,000,000 | March 6, 2021 | February 29, 2024 | CRAIGO, JODI K | reporter.nih.gov |
| Development of WecA-targeting immune potentiators to treat carbapenem-resistant Enterobacteriaceae (CRE) infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,000,000 | August 1, 2019 | July 31, 2024 | ROEMER, TERRY | reporter.nih.gov |
| A new class of antibiotic to address Antimicrobial Resistance | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,999,995 | May 1, 2024 | April 30, 2027 | TESTA, CHARLES | reporter.nih.gov |
| ELD607 Orai1 Antagonist Increases Bacterial Clearance from the Lung | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,988,078 | June 22, 2020 | June 30, 2025 | TARRAN, ROBERT | reporter.nih.gov |
| Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,977,893 | February 22, 2017 | January 31, 2024 | HARDING, CHRISTIAN | reporter.nih.gov |
| Lung Macrophage Memory Development and Responses in Secondary Pneumonia and Sepsis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $1,972,366 | August 27, 2021 | July 31, 2026 | MISHRA, BIBHUTI BHUSAN | reporter.nih.gov |
| CMC of Peptide Formulation for the Treatment of ARDS | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $1,967,733 | June 1, 2022 | May 31, 2025 | CASTILLO, GERARDO M. | reporter.nih.gov |
| The role of neutrophils in the age-driven decline in anti-pneumococcal vaccine responses | NIH | National Institute on Aging | 2021 to 2025 | $1,966,375 | September 30, 2021 | May 31, 2027 | BOU GHANEM, ELSA | reporter.nih.gov |
| Tissue niches for ILC3 development in newborn's lung | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $1,949,066 | January 1, 2021 | March 14, 2025 | DESHMUKH, HITESH | reporter.nih.gov |
| Microbiota Regulation of Pulmonary Complications Post-HCT | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $1,941,600 | September 20, 2021 | August 31, 2026 | ZHOU, XIAOFENG | reporter.nih.gov |
| Improved Therapeutics and Diagnostics for Pneumocystis Pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,932,841 | February 1, 2016 | October 31, 2026 | KOLLS, JAY K | reporter.nih.gov |
| Impact of Aging on Oxysterol Regulation of Alveolar Macrophage Function during S. pneumoniae | NIH | National Institute on Aging | 2023 to 2025 | $1,932,027 | September 1, 2023 | May 31, 2028 | STOUT DELGADO, HEATHER WINONA | reporter.nih.gov |
| Molecular mechanisms underlying organ penetration in disseminated pneumococcal infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,924,214 | November 1, 2022 | October 31, 2027 | ORIHUELA, CARLOS J | reporter.nih.gov |
| Elucidating the role of type I interferon signaling and macrophage-derived inflammation in the juvenile host with viral pneumonia | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,898,753 | May 8, 2023 | February 28, 2027 | COATES, BRIA M | reporter.nih.gov |
| Colistin resistance in extensively drug-resistant Gram-negative pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,869,812 | March 15, 2014 | March 31, 2025 | DOI, YOHEI | reporter.nih.gov |
| Common Post-Infectious Premature Epigenetic Aging | NIH | National Institute on Aging | 2023 to 2025 | $1,844,091 | August 15, 2023 | April 30, 2028 | DINARDO, ANDREW R | reporter.nih.gov |
| Siderophore based molecular imaging of pulmonary infections | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,833,928 | July 1, 2023 | June 30, 2028 | KOTAGIRI, NALINIKANTH | reporter.nih.gov |
| Antibiotic tolerance: membraneless organelles and autolysin regulation | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,820,000 | May 5, 2022 | April 30, 2027 | TUOMANEN, ELAINE I | reporter.nih.gov |
| Lead optimization of a novel cyclic aryl-indole efflux pump inhibitor (EPI) series in combination with levofloxacin against Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,799,789 | May 1, 2024 | April 30, 2027 | PARHI, AJIT K | reporter.nih.gov |
| DEVELOPMENT OF A LIPOSOMAL PNEUMOCOCCAL VACCINE FOR CLINICAL READINESS | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,796,584 | April 24, 2020 | March 31, 2023 | JONES, CHARLES HOUSTON | reporter.nih.gov |
| Endolysins as tools to eradicate pneumococcal biofilms and development ofprotective immunity | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,770,586 | December 9, 2022 | November 30, 2027 | GONZALEZ-JUARBE, NORBERTO | reporter.nih.gov |
| Molecular Mechanisms Regulating Bacterial Two-component Signaling Systems | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,766,612 | February 8, 2023 | January 31, 2028 | FUENTES, ERNESTO JORGE | reporter.nih.gov |
| Therapeutic Use of High Molecular Weight Hyaluronic Acid in Acute Lung Injury Following Severe Bacterial Pneumonia or Sepsis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,737,261 | May 1, 2020 | August 31, 2023 | LEE, JAE WOO | reporter.nih.gov |
| Mechanism and targeting of inflammasome activation in lung inflammation and injury | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,696,153 | February 16, 2023 | January 31, 2028 | LIU, GANG | reporter.nih.gov |
| Legionella effectors reveal novel signaling function for the ribosome quality control (RQC) pathway | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $1,677,236 | June 15, 2016 | May 31, 2025 | MUKHERJEE, SHAERI | reporter.nih.gov |
| A redox-sensitive switch in the macrophage nucleus regulates acute phase inflammatory injury | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $1,671,361 | June 1, 2022 | May 31, 2026 | BONINI, MARCELO G. | reporter.nih.gov |
| PspA binds necroptotic cells to cause disease and transmit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,641,325 | September 24, 2020 | August 31, 2025 | ORIHUELA, CARLOS J | reporter.nih.gov |
| Impact of nucleotide metabolism on bacterial clearance | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $1,637,144 | August 15, 2022 | July 31, 2027 | RIQUELME COLET, SEBASTIAN ALEJANDRO | reporter.nih.gov |
| A Phase II Study Evaluating the Safety and Efficacy of Whole-Cell Pneumococcal Vaccine (wSp) in Reducing Nasopharyngeal Colonization by Streptococcus pneumoniae in Young Children | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,616,462 | March 15, 2024 | February 29, 2028 | PICHICHERO, MICHAEL E | reporter.nih.gov |
| Liposomal Encapsulation Vaccine Design for Pneumococcal Disease in Aged Subjects | NIH | National Institute on Aging | 2022 to 2025 | $1,602,868 | August 4, 2022 | April 30, 2027 | PFEIFER, BLAINE A. | reporter.nih.gov |
| Inflammatory mechanisms responsible for the development of multiple organ dysfunction in pediatric patients following allogeneic blood and marrow transplantation (BMT). | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $1,598,857 | February 1, 2020 | January 31, 2026 | COOKE, KENNETH R | reporter.nih.gov |
| Novel Biamyxins targeting multidrug resistant Gram-negative bacterial infections | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,596,741 | July 2, 2024 | June 30, 2029 | ZHAO, YANAN | reporter.nih.gov |
| Integrated Analysis of Microbial and Genomic data in Obstructive Lung Disease (I AM GOLD) Study | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,595,582 | September 15, 2019 | July 31, 2025 | HUANG, LAURENCE | reporter.nih.gov |
| Development of RespiraClear for targeted mucosal treatment of RSV infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,549,957 | August 19, 2019 | April 30, 2024 | CONE, RICHARD | reporter.nih.gov |
| Acquired CFTR Dysfunction in Alcohol-related Lung Pathology | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2024 | $1,544,404 | January 1, 2020 | December 31, 2024 | RAJU, S.VAMSEE | reporter.nih.gov |
| Acidosis in pulmonary endothelial injury and repair | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,540,000 | February 1, 2022 | January 31, 2027 | LEE, JI YOUNG | reporter.nih.gov |
| Structure-function analysis of type IVB secretion systems | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,535,493 | June 10, 2019 | May 31, 2025 | CAPARON, MICHAEL G. | reporter.nih.gov |
| 1/2 WIN Ratio Analysis to Determine a Strategy of Non-Invasive SUpport for Respiratory Failure in the EmeRgency Department (WINDSURFER) | NIH | National Heart, Lung, and Blood Institute | 2025 | $1,535,439 | September 15, 2025 | December 31, 2026 | WANG, HENRY E. | reporter.nih.gov |
| Defective Zn Homeostasis impairs host defense against pneumococcal pneumonia | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,534,270 | December 22, 2021 | November 30, 2026 | KNOELL, DAREN LEE | reporter.nih.gov |
| Fibrin in the Infected Lung | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,530,164 | February 15, 2024 | January 31, 2028 | MIZGERD, JOSEPH P | reporter.nih.gov |
| Targeting ABL kinases to regulate epithelial cell plasticity and regeneration following injury | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,520,108 | June 1, 2020 | April 30, 2024 | PENDERGAST, ANN MARIE | reporter.nih.gov |
| Serological Biomarkers for Coccidioidomycosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,518,970 | June 7, 2021 | May 31, 2026 | MAGEE, D MITCHELL | reporter.nih.gov |
| Uncovering and understanding the many functions of ICAM-1 in the lungs during homeostasis and innate immune responses | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,518,050 | August 26, 2024 | May 31, 2028 | DOERSCHUK, CLAIRE M | reporter.nih.gov |
| E3 Ligase-Mediated Immunosuppression in Acute Lung Injury | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,507,608 | February 1, 2010 | June 30, 2026 | MALLAMPALLI, RAMA K | reporter.nih.gov |
| Identifying host and viral correlates for coronavirus pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,493,658 | June 15, 2020 | May 31, 2025 | JOHNSON, BRYAN A | reporter.nih.gov |
| Impact of Heightened UPR Activation on Inflammasome Responses to Influenza and Secondary Streptococcus pneumoniae Infection in Aged Lung | NIH | National Institute on Aging | 2021 to 2022 | $1,491,600 | May 1, 2018 | April 30, 2024 | STOUT DELGADO, HEATHER WINONA | reporter.nih.gov |
| Novel coenzyme Q6 variant reveals non-immune determinants of survival during pneumococcal sepsis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,481,057 | August 26, 2024 | July 31, 2028 | MORLEY, SHARON CELESTE | reporter.nih.gov |
| Complement-mediated anti-pneumococcal functions of C-reactive protein | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,480,000 | February 5, 2020 | January 31, 2026 | SINGH, SANJAY KUMAR | reporter.nih.gov |
| Airway Prevotella enhance innate immune-mediated protection against lung infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,475,007 | March 20, 2023 | February 29, 2028 | CLARK, SARAH E | reporter.nih.gov |
| A rationally-designed, live-attenuated RSV vaccine for the elderly | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,474,810 | August 16, 2017 | June 30, 2025 | MUELLER, STEFFEN | reporter.nih.gov |
| Reducing Infection Susceptibility by Immune Function Restoration in Spinal Cord Injury | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,459,520 | July 1, 2020 | June 30, 2025 | SCHWAB, JAN | reporter.nih.gov |
| Immunotherapy of KPC Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,459,263 | August 1, 2020 | July 31, 2025 | KOLLS, JAY K | reporter.nih.gov |
| Soluble adenylyl cyclases in lung endothelial tauopathy | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,451,396 | March 20, 2023 | February 28, 2027 | STEVENS, TROY | reporter.nih.gov |
| Inflammatory Organ Injury after Pneumonia-Derived Sepsis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,430,432 | July 1, 2024 | May 31, 2029 | JEYASEELAN, SAMITHAMBY | reporter.nih.gov |
| NK cell inflammation resolution circuits in pediatric RSV infection | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,426,494 | December 1, 2023 | November 30, 2028 | DUVALL, MELODY G. | reporter.nih.gov |
| Mechanisms of actin cytoskeleton modulation by Pneumoviruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,425,119 | June 1, 2018 | May 31, 2024 | DUTCH, REBECCA E. | reporter.nih.gov |
| Antibody mediated immunity against Klebsiella pneumoniae | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,424,123 | December 1, 2023 | October 31, 2028 | HARRIS, JASON B | reporter.nih.gov |
| Lung-resident antibacterial heterotypic immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,423,673 | July 1, 2015 | June 30, 2025 | MIZGERD, JOSEPH P | reporter.nih.gov |
| Surprising Efficacy of Discounted Antibiotics vs. MDR Gram-Negative Pathogens Occurring Through Innate Immune Sensitization | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,422,000 | August 1, 2020 | July 31, 2025 | NIZET, VICTOR | reporter.nih.gov |
| Airway metabolites shape susceptibility to pneumonia | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,408,116 | April 1, 2024 | March 31, 2028 | PRINCE, ALICE S | reporter.nih.gov |
| Messenger RNA capping and methylation in pneumoviruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,407,102 | December 1, 2010 | January 31, 2025 | LI, JIANRONG | reporter.nih.gov |
| Epitope and mechanistic correlates of broadly protective human antibodies for pneumococcal infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,369,933 | November 1, 2022 | October 31, 2028 | MOUSA, JARROD | reporter.nih.gov |
| Unique ADP-ribosylating and vacuolating properties of Mycoplasma pneumoniae CARDS toxin trigger airway inflammation and disease progression | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,368,330 | March 1, 2019 | February 28, 2026 | KANNAN, THIRUMALAI RENGASAMY | reporter.nih.gov |
| Understanding hypermucoviscosity in Klebsiella | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,358,649 | July 16, 2020 | September 30, 2024 | MILLER, VIRGINIA L | reporter.nih.gov |
| Vaccine immunity and inflammation in the aging person living with HIV | NIH | National Institute on Aging | 2024 to 2025 | $1,337,478 | July 15, 2024 | June 30, 2029 | FROSCH, ANNE ELIZABETH PARKER | reporter.nih.gov |
| Epidemiology, transmission and immunology of COVID-19 in nursing home residents | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,332,423 | July 23, 2020 | November 30, 2023 | CANADAY, DAVID H | reporter.nih.gov |
| Molecular mechanism of cardiac inflammation and dysfunction in Pseudomonas aeruginosa infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,319,211 | July 1, 2019 | June 30, 2025 | RAJARAM, MURUGESAN | reporter.nih.gov |
| Emerging methods and applications for test-negative studies of of infectious disease interventions | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,313,010 | July 17, 2020 | June 30, 2025 | JEWELL, NICHOLAS P | reporter.nih.gov |
| Immunotherapy for acute lung injury secondary to influenza | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,310,316 | April 1, 2020 | March 31, 2025 | KNIGHT III, PAUL R | reporter.nih.gov |
| Cell surface biogenesis in Streptococcus pneumoniae | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,290,258 | January 1, 2019 | December 31, 2024 | RUDNER, DAVID Z | reporter.nih.gov |
| Novel strategies to mitigate cardiac damage and dysfunction following invasive pneumococcal disease | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,289,472 | May 25, 2024 | June 1, 2025 | LAL, HIND | reporter.nih.gov |
| Intersection of Severe Respiratory Infection and Viral Latency | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,280,794 | June 12, 2024 | April 30, 2029 | STEED, ASHLEY | reporter.nih.gov |
| A Regulatory Cascade that Controls Pneumococcal Capsule Biosynthesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,270,445 | August 23, 2019 | July 31, 2024 | ULIJASZ, ANDREW T | reporter.nih.gov |
| Developmental Exposures to Arsenic: Pneumonia, Immunity, and Microbiomes (DEAPIM) | NIH | National Institute of Environmental Health Sciences | 2021 to 2022 | $1,248,392 | March 10, 2021 | July 31, 2022 | PARVEZ, MUHAMMAD F | reporter.nih.gov |
| Glypicans in Bacterial Lung Infection | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,247,722 | April 1, 2024 | March 31, 2028 | PARK, PYONG WOO | reporter.nih.gov |
| Mechanisms of hypervirulent Klebsiella pneumoniae gastrointestinal colonization and dissemination | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $1,240,075 | June 14, 2023 | May 31, 2025 | ZAFAR, MUHAMMAD AMMAR | reporter.nih.gov |
| Host nutrients permit immune evasion of NKT cell anti-bacterial responses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,230,778 | January 17, 2018 | December 31, 2022 | KRONENBERG, MITCHELL | reporter.nih.gov |
| Immune signatures of vaccine responses in children with sickle cell disease | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,228,468 | December 1, 2023 | October 31, 2028 | YILDIRIM, INCI BURCIN | reporter.nih.gov |
| Mitochondrial metabolism controls alveolar epithelial cell fate | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,227,550 | September 1, 2024 | August 31, 2029 | HAN, SEUNGHYE | reporter.nih.gov |
| Deciphering the Role of Rgg in the Pneumococcal Signaling, Colonization and Virulence Portfolio | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,213,672 | May 23, 2019 | April 30, 2025 | HILLER, NATALIA LUISA | reporter.nih.gov |
| C-terminal proteolysis in the Pseudomonas aeruginosa cell envelope | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,212,063 | January 1, 2018 | December 31, 2024 | DARWIN, ANDREW J. | reporter.nih.gov |
| Analyzing Adult Pneumococcal Vaccination Implementation in the Underserved | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,185,730 | June 1, 2020 | May 31, 2025 | SMITH, KENNETH J | reporter.nih.gov |
| The role of hepoxilin A3 in neutrophil breach of the Infected airway mucosa. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,184,750 | February 8, 2012 | May 31, 2024 | HURLEY, BRYAN P | reporter.nih.gov |
| Macrophage Signaling Pathways in Acute Lung Injury and Resolution | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,180,500 | March 1, 2019 | February 29, 2024 | MANICONE, ANNE M. | reporter.nih.gov |
| Trafficking and function of macrophage subpopulations within the lung microenvironment during pneumonia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,171,522 | January 1, 2019 | December 31, 2024 | DOERSCHUK, CLAIRE M | reporter.nih.gov |
| Innate Immunity in Lung Infection-induced Sepsis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $1,170,976 | June 1, 2018 | May 31, 2025 | JEYASEELAN, SAMITHAMBY | reporter.nih.gov |
| Persistent Post-Viral State of Bacterial Pneumonia Susceptibility and Severity in Down Syndrome | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,166,250 | June 1, 2019 | May 31, 2024 | YEAGER, MICHAEL E. | reporter.nih.gov |
| The MUltidimenSional phenotyping In Critical care (MUSIC) Consortium: A pathway to precision medicine at the bedside | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,162,536 | May 1, 2023 | April 30, 2029 | WARE, LORRAINE B | reporter.nih.gov |
| Synergistic control of acute respiratory pathogens by bacteriophage and the innate immune response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,156,797 | August 22, 2019 | January 1, 2024 | WEITZ, JOSHUA | reporter.nih.gov |
| Pathogenic role of IL-17 response in Streptococcus pneumoniae nasopharyngeal pathogenesis during an influenza virus co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $1,152,158 | December 3, 2019 | November 30, 2025 | KHAN, NADEEM | reporter.nih.gov |
| Protein Transport Across Membrane by Bacterial Pathogens | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $1,149,661 | July 7, 2023 | April 30, 2028 | DURIE, CLARISSA LYNN | reporter.nih.gov |
| Defining the Role of the Plasminogen Activator Protease in the Early Events that Establish Primary Pneumonic Plague | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,149,651 | May 1, 2021 | July 31, 2024 | PECHOUS, ROGER D | reporter.nih.gov |
| Colorado APS Clinical Center | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,144,687 | May 1, 2023 | April 30, 2029 | MOSS, MARC | reporter.nih.gov |
| Phenotyping ARDS, Pneumonia, and Sepsis over time to elucidate shared and distinct trajectories ofillness and recovery | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,144,421 | May 1, 2023 | April 30, 2029 | MEYER, NUALA JENNINGS | reporter.nih.gov |
| Mechanisms of host protection against pathogen-associated proteases in acute lung injury | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,142,264 | August 1, 2017 | December 31, 2022 | LEE, JANET SOJUNG | reporter.nih.gov |
| Great Lakes Clinical Center of the Acute Respiratory Distress Syndrome, Pneumonia and Sepsis (APS) Consortium | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,140,945 | May 1, 2023 | April 30, 2029 | HYZY, ROBERT C | reporter.nih.gov |
| The Intermountain West-Atlantic Center (InterACT) for the APS Phenotyping Consortium | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,133,343 | May 1, 2023 | April 30, 2029 | BROWN, SAMUEL MORRIS | reporter.nih.gov |
| Human B1-like Cells and Pneumococcal Defense in the Elderly | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,132,500 | February 1, 2019 | January 31, 2025 | ROTHSTEIN, THOMAS L | reporter.nih.gov |
| Sex Determines Age-related Changes in the Repertoire and Function of Natural Antibodies Protective against Streptococcus pneumoniae with Increasing Age | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,132,500 | September 21, 2020 | August 31, 2024 | HOLODICK, NICHOL ELIZABETH | reporter.nih.gov |
| The vital role of T403 phosphorylation of STAT2 in post-viral bacterial pneumonia | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,127,000 | March 20, 2024 | February 28, 2029 | WANG, YUXIN | reporter.nih.gov |
| Protecting Endogenous Recovery from the "Infectious Insult" in Spinal Cord Injury | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,121,721 | September 20, 2024 | August 31, 2029 | FILOUS, ANGELA R | reporter.nih.gov |
| Atlas of efflux and permeation determinants to advance antibacterial therapeutic discovery | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,120,070 | July 21, 2025 | June 30, 2030 | ZGURSKAYA, HELEN I | reporter.nih.gov |
| Molecular Phenotyping of ARDS, Pneumonia, and Sepsis using Latent Class Analysis and Metagenomic Sequencing | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,118,088 | May 1, 2023 | April 30, 2029 | CALFEE, CAROLYN | reporter.nih.gov |
| Mechanisms of host protection against pathogen-associated proteases in acute lung injury | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $1,115,035 | September 1, 2016 | August 31, 2025 | LEE, JANET SOJUNG | reporter.nih.gov |
| Influenza regulation of epithelial pneumococcal host defense. | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,113,750 | September 10, 2020 | August 31, 2025 | HARROD, KEVIN S | reporter.nih.gov |
| Respiratory Syncytial Virus Targeting of the Human Airway Epithelium | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,109,490 | December 1, 2011 | December 31, 2024 | PEEPLES, MARK E. | reporter.nih.gov |
| Developing a Novel E3 Ligase based Anti-inflammatory for ARDS | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $1,102,297 | February 1, 2022 | January 31, 2025 | MALLAMPALLI, RAMA K | reporter.nih.gov |
| Control of Influenza Infection by Lipid Mediators and Macrophages | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,099,522 | January 10, 2018 | December 31, 2024 | HAHN, YOUNG S. | reporter.nih.gov |
| The role of circadian clock proteins in innate and adaptive immunity | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $1,096,430 | September 26, 2022 | July 31, 2026 | ROSENGART, MATTHEW RANDALL | reporter.nih.gov |
| Regulation of Legionella pneumophila pathogenesis by the central eukaryotic metabolic checkpoint kinase Mechanistic Target of Rapamycin (MTOR) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,095,000 | February 11, 2019 | January 31, 2025 | IVANOV, STANIMIR STEFANOV | reporter.nih.gov |
| Lung-derived complement in pneumonia | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $1,073,597 | May 19, 2023 | April 30, 2028 | KULKARNI, HRISHIKESH SATISH | reporter.nih.gov |
| 2/1 Arrest Respiratory Failure due to Pneumonia (ARREST PNEUMONIA) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,068,366 | September 15, 2019 | August 31, 2025 | DESAI, MANISHA | reporter.nih.gov |
| CD4+ T cell Immunity in the Respiratory Tract | NIH | National Heart, Lung, and Blood Institute | 2025 | $1,063,324 | June 5, 2025 | May 31, 2032 | KOLLS, JAY K | reporter.nih.gov |
| Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,045,564 | June 20, 2017 | April 30, 2023 | TESTA, CHARLES | reporter.nih.gov |
| The BLAAST Trial: Bangladesh Lung Auscultation AI for Antibiotic Stewardship Randomized Controlled Trial | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $1,038,588 | September 1, 2024 | May 31, 2029 | MCCOLLUM, ERIC DOUGLASS | reporter.nih.gov |
| Controlling bactermic pneumococcal pneumonia with synthetic dominant-negative competence peptides | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,023,618 | April 1, 2019 | March 31, 2024 | LAU, GEE W | reporter.nih.gov |
| Establishing and Implementing Pneumonia Diagnosis in ED Older Adults: A Mixed Methods Approach | NIH | National Institute on Aging | 2022 to 2025 | $1,018,845 | September 15, 2022 | June 30, 2027 | BUCK, KATHERINE HUNOLD | reporter.nih.gov |
| Development of IN-003PI as passive immunization against human metapneumovirus infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,013,468 | September 1, 2025 | July 31, 2028 | HUTCHINS, JEFF T | reporter.nih.gov |
| Development of VLP vaccine for RSV | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,000,000 | February 15, 2014 | February 28, 2024 | BLANCO, JORGE C | reporter.nih.gov |
| A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,000,000 | January 1, 2022 | August 31, 2028 | HARDING, CHRISTIAN | reporter.nih.gov |
| Influence of polysialic acid on leukocyte migration | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $999,737 | June 1, 2018 | May 31, 2024 | STAMATOS, NICHOLAS MILTON | reporter.nih.gov |
| Therapeutic Antibody for RSV IIB | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $997,704 | February 1, 2016 | November 30, 2021 | KAUVAR, LAWRENCE MICHAEL | reporter.nih.gov |
| Bacterial Cell Wall Composition and the Influence of Antibiotics | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $997,488 | September 1, 2016 | May 31, 2025 | CEGELSKI, LYNETTE S | reporter.nih.gov |
| In vivo dose finding for IN-002 in neonatal lambs for inhaled immunotherapy of RSV | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $995,652 | August 20, 2018 | November 30, 2022 | CONE, RICHARD | reporter.nih.gov |
| LncRNA regulates lung inflammation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $983,168 | September 1, 2019 | June 30, 2025 | JIN, YANG | reporter.nih.gov |
| MycoMEIA - Urine Diagnostic for Aspergillosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $976,576 | March 8, 2021 | February 28, 2023 | MARR, KIEREN A. | reporter.nih.gov |
| The role of sex in the life cycle and transmission of Pneumocystis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $965,843 | February 1, 2019 | January 31, 2024 | CUSHION, MELANIE T | reporter.nih.gov |
| The impact of dietary zinc deficiency on innate immunity to lung infection | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $954,119 | February 1, 2021 | January 31, 2025 | PALMER, LAUREN DISTERHOFT | reporter.nih.gov |
| Preclinical Pulmonary Fibrosis, an opportune rare disease cohort | NIH | National Heart, Lung, and Blood Institute | 2021 | $944,445 | August 1, 2020 | July 31, 2022 | SCHWARTZ, DAVID ALBERT | reporter.nih.gov |
| Role of ERK1/2 signaling in SARS-CoV-2 -induced dysregulated immunity and lung pathology. | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $930,578 | September 6, 2024 | June 30, 2029 | CHANNAPPANAVAR, RUDRAGOUDA | reporter.nih.gov |
| The Role of Sex Dimorphism in Post-TBI Bacterial Pneumonia | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $928,637 | September 21, 2018 | August 31, 2025 | WAGENER, BRANT M | reporter.nih.gov |
| Endolysins as tools to eradicate pneumococcal biofilms and development of protective immunity | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $901,010 | December 9, 2022 | November 30, 2023 | GONZALEZ-JUARBE, NORBERTO | reporter.nih.gov |
| Predictive Modeling of Influenza-Pneumococcal Coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $885,870 | July 1, 2018 | June 30, 2024 | SMITH, AMBER M | reporter.nih.gov |
| Enhancing neutrophil function in neutropenia-related pneumonia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $885,000 | August 1, 2009 | April 30, 2024 | LUO, HONGBO R | reporter.nih.gov |
| Dissecting the host-plasmid interplay to unravel the spread of ESBL-producing K. pneumoniae | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $874,998 | August 13, 2025 | June 30, 2030 | KREISWIRTH, BARRY NEAL | reporter.nih.gov |
| Development of a broad spectrum teixobactin-lipopeptide hybrid for the treatment of lung infections caused by pan-drug resistant ‘superbugs’ | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $860,629 | June 21, 2022 | August 18, 2023 | RAO, GAURI G | reporter.nih.gov |
| Pediatric Recovery After Sepsis Treatment in the Pediatric Intensive Care Unit | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $859,700 | September 1, 2022 | August 31, 2026 | PERRY-EADDY, MALLORY A | reporter.nih.gov |
| Predisposition for Lung Injury in Sepsis Survival | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $847,800 | May 1, 2021 | April 30, 2026 | DENSTAEDT, SCOTT JOHN | reporter.nih.gov |
| Development of neonatal innate lung defenses is dependent on gastrointestinal commensal bacteria | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $835,296 | September 1, 2018 | August 31, 2024 | DESHMUKH, HITESH | reporter.nih.gov |
| The NF-kappaB modulator PDLIM2 as an intrinsic checkpoint of alveolar macrophages critical for lung innate immunity, inflammation and diseases | NIH | National Heart, Lung, and Blood Institute | 2025 | $829,998 | April 1, 2025 | January 31, 2029 | QU, ZHAOXIA | reporter.nih.gov |
| Epitope and mechanistic correlates of broadly protective human antibodies for pneumococcal infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $828,509 | November 1, 2022 | November 30, 2023 | MOUSA, JARROD | reporter.nih.gov |
| Targeting Angiopoietin-like 4 (ANGPTL4) in Severe Community Acquired Pneumonia | NIH | National Heart, Lung, and Blood Institute | 2025 | $827,909 | April 4, 2025 | January 31, 2029 | BHATRAJU, PAVAN KUMAR | reporter.nih.gov |
| New genetic models for C5a receptors | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $825,000 | July 1, 2018 | June 30, 2024 | BOSMANN, MARKUS | reporter.nih.gov |
| Beta-Lactamase Inhibitors Sensitize Multidrug-Resistant Gram-negative Pathogens to Innate Immune Clearance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $820,829 | April 1, 2020 | March 31, 2026 | ULLOA, ERLINDA ROSE | reporter.nih.gov |
| Lung vascular ILC3 subpopulation in anti-bacteria immunity and vasculature regeneration | NIH | National Heart, Lung, and Blood Institute | 2025 | $814,387 | August 1, 2025 | April 30, 2029 | HUANG, YUEFENG | reporter.nih.gov |
| Mechanisms of regulatory T-cell mediated endothelial repair following viral pneumonia in aged hosts | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $805,882 | September 20, 2021 | August 31, 2026 | MORALES-NEBREDA, LUISA | reporter.nih.gov |
| The oxidation of heme-carrying proteins in the pathophysiology of pneumococcal disease | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $805,442 | November 20, 2023 | October 31, 2028 | VIDAL, JORGE EUGENIO | reporter.nih.gov |
| Pulmonary gamma-delta T cells in lung infection | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $804,060 | June 15, 2021 | May 31, 2027 | WRIGHT, SHELTON WILEY | reporter.nih.gov |
| Optimizing Medications and Lung Health in People with HIV through Pharmacist-led Proactive E-Consults (OPTIMIZE Lung-HIV) | NIH | National Heart, Lung, and Blood Institute | 2025 | $803,801 | August 15, 2025 | May 31, 2030 | CROTHERS, KRISTINA ANNE | reporter.nih.gov |
| Protecting Patients with Glomerular Disease from Vaccine-Preventable Infections | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $795,246 | February 15, 2022 | January 31, 2027 | GLENN, DOREY | reporter.nih.gov |
| Randomized Trial of Endotracheal Tubes to Prevent Ventilator-Associated Pneumonia - Prevent 2 Study | NIH | National Heart, Lung, and Blood Institute | 2021 | $793,344 | June 1, 2020 | May 31, 2022 | TREGGIARI, MIRIAM | reporter.nih.gov |
| Identifying Novel Roles and the Therapeutic Potential of the Thrombin Receptor Protease Activated Receptor-1 (PAR1) in Lung Lymphatic Function and Acute Respiratory Distress Syndrome | NIH | National Heart, Lung, and Blood Institute | 2025 | $791,503 | September 15, 2025 | June 30, 2029 | REED, HASINA OUTTZ | reporter.nih.gov |
| Elucidating the genotypic determinants and phenotypic effects of polymyxin resistance in Klebsiella pneumoniae utilizing CRISPR-Cas9 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $769,824 | July 1, 2020 | June 30, 2026 | MCCONVILLE, THOMAS HOWE | reporter.nih.gov |
| Innate immunity and inflammatory response of macrophages to Legionella infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $765,106 | September 14, 2018 | August 31, 2024 | ABU KWAIK, YOUSEF A | reporter.nih.gov |
| Migration and resolution, lung microenvironment and mechanisms: examining the diverse responses of neutrophils during S. pneumoniae pneumonia and acute lung injury | NIH | National Heart, Lung, and Blood Institute | 2025 | $759,983 | May 15, 2025 | February 28, 2029 | DOERSCHUK, CLAIRE M | reporter.nih.gov |
| Rational design of a unique vaccine for emerging pandemic coronaviruses | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $755,225 | December 6, 2024 | November 30, 2029 | QIAO, LIANG | reporter.nih.gov |
| Putting Implementation into context to advance the management of mechanically ventilated patients. | NIH | National Heart, Lung, and Blood Institute | 2025 | $748,970 | August 15, 2025 | May 31, 2029 | KERLIN, MEETA PRASAD | reporter.nih.gov |
| Engineering a diagnostic platform for rapid breath-based respiratory pathogen identification and treatment monitoring | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2023 | $747,000 | July 1, 2019 | June 30, 2025 | CHAN, LESLIE | reporter.nih.gov |
| Refining our understanding of antimicrobial peptide mediated disruption of the Klebsiella pneumoniae capsule | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $747,000 | August 24, 2021 | March 31, 2027 | FLEEMAN, RENEE | reporter.nih.gov |
| Mechanisms of GM-CSF-mediated metabolic regulation of monocyte function for control of pulmonary infection | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $747,000 | August 5, 2023 | July 31, 2026 | LIU, XIN | reporter.nih.gov |
| Lung epithelial cell reprogramming by CD4 T cells | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $746,997 | April 1, 2023 | March 31, 2026 | SHENOY, ANUKUL T | reporter.nih.gov |
| Randomized Trial of Endotracheal Tubes to Prevent Ventilator-Associated Pneumonia - Prevent 2 Study | NIH | National Heart, Lung, and Blood Institute | 2022 | $743,776 | September 19, 2022 | May 31, 2026 | TREGGIARI, MIRIAM | reporter.nih.gov |
| The Roles of LPS-Binding Protein Vascular Peroxidase-1 in Innate Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $742,500 | January 4, 2019 | December 31, 2023 | CHENG, GUANGJIE | reporter.nih.gov |
| Impact of Diet Induced Obesity on Acute Lung Injury | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $725,760 | January 15, 2022 | January 17, 2025 | PLATAKI, MARIA | reporter.nih.gov |
| Preclinical development of a synthetic lung surfactant dry powder aerosol for acute respiratory distress syndrome patients receiving different modes of ventilation support | NIH | National Heart, Lung, and Blood Institute | 2022 | $719,373 | September 22, 2022 | June 30, 2023 | LONGEST, P. WORTH | reporter.nih.gov |
| Pulmonary neuroimmune determinants of immunoglobulin production against pneumonia | NIH | National Heart, Lung, and Blood Institute | 2025 | $718,661 | August 1, 2025 | April 30, 2030 | JENDZJOWSKY, NICHOLAS | reporter.nih.gov |
| LOX-1 as a protective countermeasure in response to lung infection | NIH | National Heart, Lung, and Blood Institute | 2022 | $703,500 | September 19, 2022 | June 5, 2023 | QUINTON, LEE | reporter.nih.gov |
| Characterization of Rifabutin Therapy Against Antibiotic-Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $696,618 | August 10, 2018 | July 31, 2023 | LUNA, BRIAN MICHAEL | reporter.nih.gov |
| 2/2 WIN Ratio Analysis to Determine a Strategy of Non-Invasive SUpport for Respiratory Failure in the EmeRgency Department (WINDSURFER) | NIH | National Heart, Lung, and Blood Institute | 2025 | $688,047 | September 1, 2025 | August 31, 2031 | DURKALSKI, VALERIE L | reporter.nih.gov |
| Nosocomial pneumonia impairs the cerebrovasculature | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $684,527 | May 16, 2024 | May 2, 2025 | NELSON, AMY R | reporter.nih.gov |
| Targeting Estrogenic pathways in Tregs to promote ARDS resolution - 5R01HL163881 | NIH | National Heart, Lung, and Blood Institute | 2025 | $684,280 | August 15, 2025 | May 31, 2027 | D'ALESSIO, FRANCO RAFAEL | reporter.nih.gov |
| Zinc intervention in prevention of pneumonia in elderly | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $679,500 | July 1, 2021 | June 30, 2024 | PANDA, ALEXANDER | reporter.nih.gov |
| Extending neutrophil survival in neutropenia-related pneumonia | NIH | National Heart, Lung, and Blood Institute | 2025 | $676,748 | July 1, 2025 | March 31, 2029 | LUO, HONGBO R | reporter.nih.gov |
| The effect of household air pollution on lung function growth in infants with pneumonia in sub-Saharan Africa. | NIH | National Institute of Environmental Health Sciences | 2021 to 2024 | $670,862 | March 14, 2024 | February 28, 2025 | MOSCHOVIS, PETER P | reporter.nih.gov |
| The role of HMGB1 in the lung response to bacterial injury | NIH | National Heart, Lung, and Blood Institute | 2025 | $656,988 | August 1, 2025 | April 30, 2030 | MESSER, JEANNETTE SOPHIA | reporter.nih.gov |
| Full Spectrum Cell Sorter with Imaging Enhancement for Boston University Flow Cytometry Core Facility | NIH | Office of the Director, National Institutes of Health | 2025 | $656,148 | April 15, 2025 | April 14, 2026 | BELKINA, ANNA | reporter.nih.gov |
| Intrapulmonary itaconate as a host-protective metabolite during ER Stress and Klebsiella pneumoniae infection | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $642,944 | April 1, 2022 | March 31, 2027 | SUBER, TOMEKA L | reporter.nih.gov |
| SARS-CoV-2 tropism in the brain and its relationship to COVID-19 pathogenesis | NIH | National Heart, Lung, and Blood Institute | 2021 | $642,597 | September 25, 2021 | August 31, 2023 | YAKOUB, ABRAAM M. | reporter.nih.gov |
| Impaired Pneumococcal Antibody Function and Exacerbations of Chronic Obstructive Pulmonary Disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $642,128 | January 1, 2022 | December 31, 2026 | LAFON, DAVID CARDY | reporter.nih.gov |
| CD38, T cells and post viral lung sequelae during aging | NIH | National Institute on Aging | 2025 | $639,740 | December 15, 2024 | November 30, 2029 | SUN, JIE | reporter.nih.gov |
| Repertoire studies of human antibodies to RSV and MPV F | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $621,866 | September 6, 2018 | August 31, 2023 | JARDETZKY, THEODORE S | reporter.nih.gov |
| Eosinophils as Effectors of Antibacterial Immunity in the Lungs | NIH | National Heart, Lung, and Blood Institute | 2024 | $615,455 | September 1, 2024 | June 30, 2028 | SAMARASINGHE, AMALI | reporter.nih.gov |
| A redox-sensitive switch in the macrophage nucleus regulates acute phaseinflammatory injury | NIH | National Heart, Lung, and Blood Institute | 2025 | $613,814 | June 1, 2022 | May 31, 2027 | BONINI, MARCELO G. | reporter.nih.gov |
| Eosinophils as Effectors of Antibacterial Immunity in the Lungs | NIH | National Heart, Lung, and Blood Institute | 2025 | $613,501 | September 1, 2024 | June 30, 2028 | SAMARASINGHE, AMALI E | reporter.nih.gov |
| Lung Macrophage Memory Development and Responses in Secondary Pneumonia and Sepsis | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $610,868 | August 27, 2021 | July 31, 2025 | MISHRA, BIBHUTI BHUSAN | reporter.nih.gov |
| Host control mechanisms against K. pneumoniae infection in the lungs | NIH | National Heart, Lung, and Blood Institute | 2021 | $603,934 | April 1, 2018 | March 31, 2024 | CHEN, KONG | reporter.nih.gov |
| Optimize Formulation of VSA Adjuvant | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $600,000 | July 5, 2022 | July 5, 2024 | CLEMENTS, DAVID | reporter.nih.gov |
| Formulation of a prophylactic vaccine against Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $599,999 | March 16, 2022 | February 28, 2025 | NAGEL, AARON C | reporter.nih.gov |
| Mechanisms of Klebsiella pneumoniae gastrointestinal colonization | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $599,768 | June 14, 2023 | May 31, 2029 | ZAFAR, MUHAMMAD AMMAR | reporter.nih.gov |
| Pn3Pase as an Effective Enzyme Therapeutic for Streptococcus Pneumoniae type 3 Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $598,900 | July 9, 2021 | June 30, 2024 | AVCI, FIKRI Y | reporter.nih.gov |
| Development of FosA Inhibitors to Potentiate Fosfomycin Activity in Gram-Negative Pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $598,124 | August 15, 2022 | June 30, 2024 | WROBEL, JAY EDWARD | reporter.nih.gov |
| Development of Broad-Spectrum Cyclic Amphiphilic Peptides against Multidrug-Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $596,643 | August 18, 2022 | July 31, 2025 | KAZEMINY, ASSAD | reporter.nih.gov |
| Development of Coccidioides Cytokine Release Assay | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $596,247 | March 1, 2021 | February 28, 2023 | WHEAT, LAWRENCE JOSEPH | reporter.nih.gov |
| A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $593,112 | January 1, 2022 | December 31, 2024 | HARDING, CHRISTIAN | reporter.nih.gov |
| Targeted delivery of novel miRNA-based therapeutics for pneumonia-induced acute lung injury | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $583,152 | September 8, 2022 | August 31, 2025 | AKERLEY, BRIAN | reporter.nih.gov |
| Host factors influencing early clearance of Streptococcus pneumoniae from the middle ear following invasion from the nasopharynx | NIH | National Institute on Deafness and Other Communication Disorders | 2022 to 2024 | $583,125 | February 1, 2022 | July 31, 2025 | CLARK, SARAH E | reporter.nih.gov |
| Individualizing Steroid Use in Pneumonia (Supplement) | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $582,229 | June 1, 2023 | July 31, 2026 | ODEYEMI, YEWANDE | reporter.nih.gov |
| Patient-Oriented Research on Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $549,502 | July 10, 2013 | January 31, 2025 | HAUSER, ALAN R | reporter.nih.gov |
| Lung-derived complement in pneumonia | NIH | National Heart, Lung, and Blood Institute | 2025 | $546,742 | July 8, 2025 | April 30, 2028 | KULKARNI, HRISHIKESH SATISH | reporter.nih.gov |
| Targeting TLR Signaling Pathways to Blunt Pathogen-mediated Acute Lung Injury | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $544,376 | February 10, 2017 | January 31, 2023 | VOGEL, STEFANIE N. | reporter.nih.gov |
| Genetic Analysis of Legionella Phagosome Trafficking | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $544,169 | August 1, 2017 | July 31, 2023 | ROY, CRAIG R. | reporter.nih.gov |
| Netosis in Trauma mediated Acute Lung Injury | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $540,344 | September 14, 2021 | July 31, 2024 | LEONARD, JENNIFER | reporter.nih.gov |
| Consequences of Direct Viral-Bacterial Interactions | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $531,058 | July 20, 2021 | June 30, 2023 | ROSCH, JASON W. | reporter.nih.gov |
| Rational design of an adhesin-based pneumococcal vaccine targeting colonization | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $528,735 | September 17, 2020 | August 31, 2028 | THORNTON, JUSTIN A | reporter.nih.gov |
| Defining the Role of the Plasminogen Activator Protease in the Early Events that Establish Primary Pneumonic Plague | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $525,035 | May 1, 2021 | April 30, 2027 | PECHOUS, ROGER D | reporter.nih.gov |
| A 3D human tissue-engineered lung model to study immune responses to Respiratory Syncytial Virus | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 | $517,917 | September 20, 2018 | June 30, 2024 | KOVATS, SUSAN | reporter.nih.gov |
| ENaC-α mediates lung fluid clearance and capillary barrier function in pneumonia | NIH | National Heart, Lung, and Blood Institute | 2021 | $515,730 | July 1, 2018 | June 30, 2023 | LUCAS, RUDOLF | reporter.nih.gov |
| Inflammasomes: Regulation and Function in Acute Lung Injury | NIH | National Heart, Lung, and Blood Institute | 2021 | $508,492 | July 1, 1996 | March 31, 2023 | CHOI, MARY E | reporter.nih.gov |
| Elucidating the Sexual Cycle of HIV/AIDS-Related Pneumocystis Pneumonia | NIH | National Heart, Lung, and Blood Institute | 2025 | $508,041 | August 1, 2025 | May 31, 2029 | SMULIAN, ALAN GEORGE | reporter.nih.gov |
| The Function and Potential Application of Extracellular Vesicle Derived Clara Cell Protein 16 in Gram-negative Bacterial Pneumonia | NIH | National Heart, Lung, and Blood Institute | 2023 | $501,482 | September 1, 2023 | August 31, 2025 | ZHANG, DUO | reporter.nih.gov |
| Establishing Mechanisms of LOX-1-Dependent Immune Regulation During Pneumonia | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $498,000 | July 22, 2024 | June 30, 2027 | KORKMAZ, FILIZ | reporter.nih.gov |
| Understanding the immunometabolic response to Klebsiella pneumonia infection | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $497,998 | April 1, 2024 | March 31, 2027 | WONG FOK LUNG, TANIA | reporter.nih.gov |
| Lincenc1 regulates the lipopolysaccharide-induced inflammatory response in macrophages | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $495,100 | June 20, 2020 | May 31, 2024 | ZHANG, DUO | reporter.nih.gov |
| Assessing Klebsiella pneumoniae invasion of the intact gut microbiome | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $493,654 | August 5, 2021 | March 31, 2025 | VORNHAGEN, JAY | reporter.nih.gov |
| IFN/SOCS1 signaling during post-influenza bacterial infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $489,965 | September 1, 2025 | August 31, 2026 | SUN, KEER | reporter.nih.gov |
| Unravelling the role of aDb2 as a novel complement receptor in lung injury | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $489,500 | July 25, 2025 | June 30, 2027 | KOUTSOGIANNAKI, SOPHIA | reporter.nih.gov |
| Invasive Pneumococcal Disease and Carriage among Children with Sickle Cell Disease in Ghana: A Post-vaccination Study | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $489,262 | May 12, 2022 | April 30, 2027 | SAMPANE-DONKOR, ERIC | reporter.nih.gov |
| Host Response, Lung Microbiome, and Clinical Phenotype in Hypersensitivity Pneumonia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $487,290 | April 1, 2019 | February 29, 2024 | SALISBURY, MARGARET LOUISE | reporter.nih.gov |
| Identification of RNA-binding proteins in Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $486,750 | April 25, 2022 | March 31, 2025 | DOVE, SIMON L | reporter.nih.gov |
| Integrative Multi-Scale Systems Analysis of Gene-Expression-Driven Aging Morbidity | NIH | National Institute on Aging | 2024 to 2025 | $485,270 | September 15, 2020 | December 31, 2026 | STOEGER, THOMAS | reporter.nih.gov |
| Pulmonary Epithelial Dynamics and Innate Host Defense | NIH | National Heart, Lung, and Blood Institute | 2021 | $480,973 | December 7, 2017 | November 30, 2022 | MCCORMACK, FRANCIS XAVIER | reporter.nih.gov |
| Metformin to improve immunological health and vaccine responses | NIH | National Institute on Aging | 2021 to 2023 | $478,119 | May 1, 2020 | February 28, 2025 | LEE, GRACE CHOI | reporter.nih.gov |
| Impact of Pandemic Mitigation Efforts on Colonization and Transmission of Respiratory Pathogens and Antibiotic Resistance Genes | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $475,750 | June 8, 2022 | May 31, 2024 | HOWARD, LEIGH MEREDITH | reporter.nih.gov |
| The anatomy of T-cell mediated neutrophil recruitment during lung infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $472,210 | June 23, 2025 | May 31, 2027 | QUINTON, LEE | reporter.nih.gov |
| Features of PMN Senescence that Lead to Susceptibility to Pneumococcal Infection | NIH | National Institute on Aging | 2021 to 2022 | $469,115 | March 1, 2021 | February 29, 2024 | MECSAS, JOAN C | reporter.nih.gov |
| Characterization of assembly factors for type IV secretion systems | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $466,999 | June 21, 2021 | May 31, 2024 | CAPARON, MICHAEL G. | reporter.nih.gov |
| Dynactin 4 regulation of lung injury | NIH | National Heart, Lung, and Blood Institute | 2021 | $466,844 | January 1, 2018 | November 30, 2022 | CHEN, PETER | reporter.nih.gov |
| Within-host diversity of Gram negative bacteria from bloodstream infections | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $466,480 | November 21, 2023 | October 31, 2026 | NGUYEN, M. HONG THI | reporter.nih.gov |
| Antibiotic resistance among hypermutator carbapenem resistant Klebsiella pneumoniae | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $466,199 | June 21, 2022 | May 31, 2025 | NGUYEN, M. HONG THI | reporter.nih.gov |
| Autosomal dominant OTULIN deficiency and staphylococcal disease | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $466,125 | August 15, 2022 | July 31, 2024 | BOISSON, BERTRAND | reporter.nih.gov |
| Risk Stratification and Decision Support to Improve Care and Outcomes in Children with Pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $460,844 | February 7, 2017 | January 31, 2023 | WILLIAMS, DEREK J. | reporter.nih.gov |
| Reciprocal brain-lung responses in post-stroke pneumonia | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $460,625 | August 1, 2023 | July 31, 2025 | SANSING, LAUREN H | reporter.nih.gov |
| Pyocins as antibacterials to treat Pseudomonas aeruginosa infections | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $458,460 | July 1, 2023 | June 30, 2025 | GOLDBERG, JOANNA B | reporter.nih.gov |
| Innovative Antibiotic Combinations for Hypervirulent Klebsiella pneumoniae | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $456,911 | July 1, 2025 | June 30, 2027 | BULMAN, ZACKERY P. | reporter.nih.gov |
| A novel bacteria-specific pro-photosensitizer | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $456,558 | March 11, 2024 | January 31, 2027 | WU, MEI X | reporter.nih.gov |
| Spatiotemporal interrogation of interactions of pneumolysin, pulmonary epithelium, and PMNs that result in age-associated susceptibility to Streptococcus pneumoniae disease | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $450,630 | August 1, 2025 | July 31, 2027 | LEONG, JOHN M | reporter.nih.gov |
| Urovirulence and fimbrial regulation in Klebsiella quasipneumoniae | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $450,360 | August 18, 2023 | July 31, 2025 | DE NISCO, NICOLE JANELL | reporter.nih.gov |
| Deciphering the impact of sedative choice on the dynamics of Klebsiella pneumoniae lung infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $449,200 | November 16, 2021 | October 31, 2023 | FREITAG, NANCY ELIZABETH | reporter.nih.gov |
| Pulmonary Disfunction after Polysubstance Exposure: Mechanistic Identification of Inflammatory Mediators | NIH | National Institute of General Medical Sciences | 2022 to 2024 | $448,917 | July 8, 2022 | November 30, 2025 | SIVARAMAN, VIJAY | reporter.nih.gov |
| Siderophores of Legionella pneumophila | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $447,861 | July 23, 2018 | June 30, 2023 | CIANCIOTTO, NICHOLAS P | reporter.nih.gov |
| RBC-mediated mopping of cytokines for the treatment of pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $446,875 | September 24, 2021 | August 31, 2023 | BRENNER, JACOB | reporter.nih.gov |
| TNF and caspase-8-mediated control of Legionella pneumophila infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $446,667 | March 5, 2021 | February 29, 2024 | SHIN, SUNNY | reporter.nih.gov |
| Identifying niche specific adaptations in Acinetobacter baumannii | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $445,587 | March 24, 2022 | February 28, 2025 | FELDMAN, MARIO | reporter.nih.gov |
| Origin and host adaptation of the novel canine coronavirus (CCoV-HuPn-2018) isolated from a human pneumonia patient | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $445,439 | August 23, 2023 | July 31, 2025 | VLASOVA, ANASTASIA NICKOLAEVNA | reporter.nih.gov |
| Mechanisms of age-related lung inflammation in pulmonary melioidosis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $445,338 | July 23, 2025 | June 30, 2027 | WRIGHT, SHELTON WILEY | reporter.nih.gov |
| A Novel Mucosal Vaccine for Pseudomonas aeruginosa Infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $444,989 | February 1, 2022 | July 31, 2024 | ARNABOLDI, PAUL MICHAEL | reporter.nih.gov |
| Dissecting a sensory system for Legionella replication vacuole integrity | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $444,172 | May 22, 2024 | March 31, 2027 | O'CONNOR, TAMARA | reporter.nih.gov |
| Sex-Dependent Regulation of Host Factors Influencing SARS-CoV-2 Infection and COVID-19 Disease | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $442,751 | April 15, 2022 | March 31, 2024 | ANGUERA, MONTSERRAT C | reporter.nih.gov |
| HEMOGLOBIN-INDUCED VIRULENCE IN STREPTOCOCCUSPNEUMONIAE | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $441,005 | March 10, 2021 | February 29, 2024 | VIDAL, JORGE EUGENIO | reporter.nih.gov |
| Effector-triggered immunity against Legionella pneumophila in dendritic cells | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $440,625 | July 5, 2023 | June 30, 2025 | SHIN, SUNNY | reporter.nih.gov |
| Novel small-molecule inhibitors of SARS-CoV-2 protease | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $440,000 | December 1, 2020 | November 30, 2023 | SONG, YONGCHENG | reporter.nih.gov |
| Microglia mediate cognitive dysfunction in elderly survivors of pneumonia | NIH | National Institute on Aging | 2022 | $440,000 | February 1, 2022 | January 31, 2025 | MISHARIN, ALEXANDER | reporter.nih.gov |
| PIWIL4 and piRNAs in RSV Infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $440,000 | January 25, 2023 | August 31, 2025 | CASOLA, ANTONELLA | reporter.nih.gov |
| Deciphering how the Cas2 ribonuclease non-canonically controls Legionella pneumophila thermal tolerance and virulence | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $440,000 | July 8, 2024 | May 31, 2026 | CIANCIOTTO, NICHOLAS P | reporter.nih.gov |
| Microbial and Host Factors that Promote Epithelial Disruption and S. pneumoniae Transit out of the Lung | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $439,500 | April 1, 2021 | March 31, 2025 | ADAMS, WALTER ISAIAH | reporter.nih.gov |
| Rational identification of Corynebacterium strains for use as probiotics | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $439,416 | May 16, 2022 | April 30, 2025 | SEED, PATRICK C. | reporter.nih.gov |
| The Role of the EphA2 Receptor Kinase Pathway in Pneumocystis Pneumonia (PCP) | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $437,798 | November 16, 2023 | October 31, 2025 | LIMPER, ANDREW H | reporter.nih.gov |
| Early detection and identification of ventilator associated pneumonia | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $437,250 | April 15, 2023 | March 31, 2026 | CORCORAN, TIMOTHY E | reporter.nih.gov |
| Function of the Klebsiella pneumoniae RND efflux systems | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $436,990 | June 17, 2022 | May 31, 2025 | BINA, JAMES EDWARD | reporter.nih.gov |
| Inflammation-targeted delivery of corticosteroids using genetically engineered cellular nanoparticles | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $434,500 | February 8, 2023 | March 31, 2025 | FANG, RONNIE H | reporter.nih.gov |
| Negative regulation of inflammation during Klebsiella pneumoniae infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $432,980 | May 11, 2021 | April 30, 2024 | TREVEJO-NUNEZ, GIRALDINA | reporter.nih.gov |
| Use of site-specific pharmacokinetics to optimize antibiotic combinations and prevent the emergence of resistance against CRE | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $431,417 | November 24, 2020 | October 31, 2024 | SHIELDS, RYAN K | reporter.nih.gov |
| F-18 fluorodeoxysorbitol for detecting response of bacterial infection to treatment | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $429,500 | March 16, 2021 | February 29, 2024 | NG, CHIN K | reporter.nih.gov |
| Susceptibility determinants to Legionella pneumophila infection in smokers | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $429,000 | March 18, 2021 | August 31, 2023 | AMER, AMAL O | reporter.nih.gov |
| Exploring protein translocation by the Legionella pneumophila Dot/Icm Type IV Section System | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $429,000 | June 11, 2021 | May 31, 2024 | OHI, MELANIE DIANE | reporter.nih.gov |
| Small RNA based control of zinc homeostasis in Streptococcus pneumoniae | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $429,000 | May 20, 2022 | April 30, 2024 | DE LAY, NICHOLAS R. | reporter.nih.gov |
| Capsular locus deep sequencing to study Klebsiella populations | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $429,000 | August 22, 2023 | July 31, 2025 | BACHMAN, MICHAEL ABBOTT | reporter.nih.gov |
| Q223R Leptin Receptor Polymorphism in Bacterial Pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $429,000 | December 1, 2023 | October 31, 2026 | MANCUSO, PETER | reporter.nih.gov |
| Investigation of capsule interactions that promote antimicrobial peptide activity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $428,855 | March 19, 2021 | February 29, 2024 | DAVIES, BRYAN WILLIAM | reporter.nih.gov |
| Metabolomic Prediction of Pneumonia Severity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $427,625 | April 21, 2021 | March 31, 2024 | AMBROGGIO, LILLIAM | reporter.nih.gov |
| Multi-omics of murine respiratory melioidosis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $427,625 | August 1, 2023 | July 31, 2025 | WEST, TIMOTHY EOIN | reporter.nih.gov |
| Immune recognition of Klebsiella pneumoniae O2v1 and O2v2 O-antigen subtypes | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $427,625 | August 1, 2023 | July 31, 2025 | ROSEN, DAVID A. | reporter.nih.gov |
| Acinetobacter baumannii reservoirs within the host | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $427,625 | June 1, 2024 | April 30, 2026 | FELDMAN, MARIO | reporter.nih.gov |
| Elucidating the role of fimbriae in Klebsiella pneumoniae-mediated liver abscess formation | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $427,625 | July 1, 2025 | June 30, 2027 | ROWE, SARAH ELIZABETH | reporter.nih.gov |
| Antibiotic treatment failure of Klebsiella pneumoniae liver abscesses | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $427,625 | August 1, 2025 | July 31, 2027 | ROWE, SARAH ELIZABETH | reporter.nih.gov |
| Resolution of Diffuse Inflammatory Lung Injury in Neonatal Mice | NIH | National Heart, Lung, and Blood Institute | 2021 | $426,425 | June 15, 2013 | August 31, 2023 | MCGRATH-MORROW, SHARON ANN | reporter.nih.gov |
| Animal models of SARS-CoV-2 bacterial Coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $426,250 | May 16, 2022 | April 30, 2025 | XIANG, YAN | reporter.nih.gov |
| Biology of hypervirulent Klebsiella pneumoniae translocation from the gastrointestinal tract | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $426,250 | November 1, 2021 | October 31, 2024 | ZAFAR, MUHAMMAD AMMAR | reporter.nih.gov |
| The impact of aging and thymus regeneration on tissue-resident CD8 T cell responses to viral lung infection and vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $426,250 | June 1, 2022 | May 31, 2025 | GRIFFITH, ANN VENABLES | reporter.nih.gov |
| Mechanisms underlying adhesion and colonization in pneumococcal keratitis | NIH | National Eye Institute | 2023 | $426,250 | August 1, 2023 | July 31, 2025 | MARQUART, MARY E | reporter.nih.gov |
| Role of B cells in controlling Klebsiella pneumoniae associated disease states | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $426,250 | May 25, 2023 | April 30, 2026 | HAAS, KAREN M | reporter.nih.gov |
| Targeting T3SA proteins as protective antigens against Yersinia | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $425,855 | January 24, 2023 | December 31, 2025 | PICKING, WENDY L. | reporter.nih.gov |
| DeADP-ribosylation of host targets mediated by a bacterial effector | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $425,526 | January 19, 2023 | December 31, 2025 | DAS, CHITTARANJAN | reporter.nih.gov |
| Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $424,875 | May 23, 2023 | April 30, 2026 | BALIBAN, SCOTT M. | reporter.nih.gov |
| Impact of Dual Alcohol and Cannabis Use on Lung | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2022 | $423,961 | August 20, 2021 | July 31, 2024 | BURNHAM, ELLEN L | reporter.nih.gov |
| Impact of Heightened ER Stress on NLRP3 Activation in Aged Lung during Infection | NIH | National Institute on Aging | 2021 | $423,750 | September 1, 2017 | May 31, 2023 | STOUT DELGADO, HEATHER WINONA | reporter.nih.gov |
| An intranasal room stable vaccine formulation to prevent Pseudomonas aeruginosa (R21AI169691) | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $423,595 | September 1, 2023 | August 31, 2025 | PICKING, WENDY L. | reporter.nih.gov |
| The amyloid precursor protein protects against acute lung injury | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $423,500 | August 11, 2023 | July 31, 2025 | AUDIA, JONATHON PETER | reporter.nih.gov |
| The Pseudomonas aeruginosa virulence factor ExoU activates pyroptosis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $423,500 | December 1, 2023 | October 31, 2025 | AUDIA, JONATHON PETER | reporter.nih.gov |
| Addressing genetic tractability and species-specific infection biology in Chlamydia pneumoniae | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $420,750 | November 7, 2022 | June 30, 2025 | FIELDS, KENNETH A | reporter.nih.gov |
| Recent thyme emigrants mitigate viral pulmonary pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $420,750 | May 23, 2024 | March 31, 2026 | POCIASK, DEREK A | reporter.nih.gov |
| Rethinking Legionella pneumophila type IV pili and their roles in intracellular infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $420,669 | June 13, 2023 | May 31, 2025 | CIANCIOTTO, NICHOLAS P | reporter.nih.gov |
| Mucinases as Emerging Players in Legionella pneumophila Pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $420,105 | February 1, 2023 | January 31, 2025 | CIANCIOTTO, NICHOLAS P | reporter.nih.gov |
| The role of PMNs and CD73 in host-resistance against S. pneumoniae / influenza A virus co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $419,393 | February 24, 2023 | January 31, 2026 | BOU GHANEM, ELSA | reporter.nih.gov |
| Interrogation of the sRNA regulatory network mediating virulence of Streptococcus pneumoniae | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $419,275 | December 1, 2023 | October 31, 2026 | MEYER, MICHELLE MARGARET | reporter.nih.gov |
| Macrophage Redox State in Sterilizing and Injurious Inflammation | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $418,223 | April 7, 2017 | March 31, 2023 | BONINI, MARCELO G. | reporter.nih.gov |
| PNA-STAMPs: Versatile, Potent and Targeted Antibiotics | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $418,109 | August 1, 2024 | June 30, 2027 | HILLER, NATALIA LUISA | reporter.nih.gov |
| Mathematical Modeling of Influenza Severity in Outbred Mice | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $418,042 | November 25, 2020 | October 31, 2023 | ALCORN, JOHN F | reporter.nih.gov |
| Antibody therapy for pneumococcal disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $417,500 | November 10, 2016 | October 31, 2022 | PIROFSKI, LIISE-ANNE | reporter.nih.gov |
| Development and Evaluation of CRRT-Specific Precision Dosing Models to Optimize Beta-Lactam Treatment for Patients with Hospital-Acquired Pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $417,308 | June 23, 2023 | May 31, 2026 | RHODES, NATHANIEL JAMES | reporter.nih.gov |
| Integrated modeling of Klebsiella pneumoniae infections based on bacterial genotype, patient factors and colonization status | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $417,192 | February 15, 2017 | January 31, 2023 | BACHMAN, MICHAEL ABBOTT | reporter.nih.gov |
| C3 Mitigates Epithelial Injury in Pneumonia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $416,942 | September 1, 2019 | August 31, 2025 | KULKARNI, HRISHIKESH SATISH | reporter.nih.gov |
| Role of Legionella pneumophila Lvh TIVSS in virulence | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $415,060 | August 20, 2021 | May 31, 2026 | DUBYTSKA, LIDIYA | reporter.nih.gov |
| HMPV/RSV co-infection: effects on replication and viral spread | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $413,248 | August 11, 2023 | July 31, 2026 | DUTCH, REBECCA E. | reporter.nih.gov |
| In vitro PCLS models of Pneumocystis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $407,303 | June 1, 2024 | April 30, 2027 | KOLLS, JAY K | reporter.nih.gov |
| Mechanistic triggers of excessive mucus during lung infections by bacterial volatile organic compounds | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $407,208 | August 25, 2023 | July 31, 2026 | LAU, GEE W | reporter.nih.gov |
| Supplement to "New ACE2 activator and its prodrug as novel therapeutic regents for inflammatory pulmonary diseases" | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $406,756 | April 2, 2020 | December 31, 2022 | JIA, HONGPENG | reporter.nih.gov |
| Myeloid cell TRAF6 signaling in SARS-CoV-2-induced dysregulated lung immunity | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $406,438 | June 1, 2024 | April 30, 2027 | CHANNAPPANAVAR, RUDRAGOUDA | reporter.nih.gov |
| Strategies to Enhance Pneumonia Care via Intermediate Intensive Care (STEP IN) | NIH | National Heart, Lung, and Blood Institute | 2021 | $403,484 | September 1, 2017 | May 31, 2022 | COOKE, COLIN | reporter.nih.gov |
| Development of a Molecular Toolbox for Pneumocystis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $402,860 | December 1, 2024 | November 30, 2027 | SMULIAN, ALAN GEORGE | reporter.nih.gov |
| The vital role of T404 phosphorylation of STAT2 in post-viral bacterial pneumonia | NIH | National Heart, Lung, and Blood Institute | 2022 | $402,500 | September 1, 2022 | August 31, 2024 | WANG, YUXIN | reporter.nih.gov |
| Cardiomyocyte self-defense against Streptococcus pneumoniae | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $396,589 | March 7, 2023 | February 28, 2026 | ORIHUELA, CARLOS J | reporter.nih.gov |
| SSLs immune manipulation in S aureus colonization, infection, and a potential therapy against pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $392,409 | August 1, 2025 | July 31, 2030 | CHEN, CHEN | reporter.nih.gov |
| Personalizing Antimicrobial Use in Ventilator-Associated Pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $388,800 | June 18, 2024 | May 31, 2029 | ALBIN, OWEN | reporter.nih.gov |
| Bacteriophage-mediated microbiota modification to prevent colorectal cancer development | NIH | National Cancer Institute | 2022 to 2023 | $387,838 | May 10, 2022 | February 28, 2025 | EL HADDAD, LYNN | reporter.nih.gov |
| Electronic Cigarette Vapor Inhalation Adversely Affects Lung Cellular and Physiologic Function and Alters Systemic Inflammatory Pathways | NIH | National Heart, Lung, and Blood Institute | 2021 | $387,500 | April 1, 2017 | December 31, 2022 | CROTTY ALEXANDER, LAURA ELISE | reporter.nih.gov |
| Novel antimicrobials to combat Gram-negative bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $383,750 | August 16, 2023 | July 31, 2025 | WANG, GUANGSHUN | reporter.nih.gov |
| Regulation of phosphodiesterases and cAMP signaling during the host-pathogen interaction in the pulmonary endothelium | NIH | National Heart, Lung, and Blood Institute | 2021 | $378,245 | April 1, 2018 | March 31, 2023 | RICHTER, WITO H | reporter.nih.gov |
| Molecular and cellular mechanism regulating innate immunity and inflammation during pattern recognition receptor activation and respiratory virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $375,233 | June 1, 2010 | July 31, 2024 | BOSE, SANTANU | reporter.nih.gov |
| Development of LspA Inhibitors to Treat Gram-negative Bacterial Infections | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $374,000 | July 1, 2022 | June 30, 2024 | SUTTERLIN, HOLLY ANN | reporter.nih.gov |
| The role of circadian clock proteins in innate and adaptive immunity | NIH | National Institute of General Medical Sciences | 2022 | $373,588 | September 26, 2022 | June 30, 2023 | ROSENGART, MATTHEW RANDALL | reporter.nih.gov |
| Molecular Mechanism of Lung Barrier Dysfunction | NIH | National Heart, Lung, and Blood Institute | 2021 | $371,250 | July 1, 2018 | May 31, 2024 | DING, QIANG | reporter.nih.gov |
| Pneumococcal dynamics in the conjugate vaccine era: Addressing unanswered questions | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $368,213 | January 17, 2019 | December 31, 2023 | HOWARD, LEIGH MEREDITH | reporter.nih.gov |
| Development and implementation of a pediatric AI multi-modal digital stethoscope and respiratory surveillance system in South Africa | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 | $367,680 | August 7, 2023 | July 31, 2025 | MCCOLLUM, ERIC DOUGLASS | reporter.nih.gov |
| Host Response and Immunity to Yersenia pestis Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $365,222 | May 8, 2017 | April 30, 2023 | ANDERSON, DEBORAH M | reporter.nih.gov |
| A parainfluenza virus 5 (PIV5)-based bivalent vaccine for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $358,875 | September 5, 2023 | August 31, 2025 | GINGERICH, MARIA CRISTINA | reporter.nih.gov |
| Pathogenic role of IL-17 response in Streptococcus pneumoniae nasopharyngeal pathogenesis during an influenza virus co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $357,081 | December 3, 2019 | November 30, 2024 | KHAN, NADEEM | reporter.nih.gov |
| Role of epigenetic changes in intracellular survival and replication of Legionell pneumophila | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $354,650 | September 1, 2024 | August 31, 2028 | BANGA, SIMRAN | reporter.nih.gov |
| Procalcitonin to Reduce Antibiotic Use in Pediatric Pneumonia (P-RAPP) | NIH | National Heart, Lung, and Blood Institute | 2021 | $353,127 | September 1, 2020 | June 30, 2022 | FLORIN, TODD ADAM | reporter.nih.gov |
| Glycan-Lectin Receptor Regulation of Macrophage Maturation and Lung InnateDefenses in the Fetus and Newborn Infant | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $348,400 | July 17, 2019 | June 30, 2023 | PRINCE, LAWRENCE S | reporter.nih.gov |
| Alveolar organoids and metabolomic-driven cultivation of Pneumocystis species | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $344,534 | December 20, 2024 | November 30, 2027 | SMULIAN, ALAN GEORGE | reporter.nih.gov |
| The Effect of Maternal Cells on Infant Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $341,450 | December 12, 2017 | July 31, 2023 | HARRINGTON, WHITNEY ELIZABETH | reporter.nih.gov |
| Precision medicine approaches in the diagnosis of community-acquired pneumonia in children | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $335,920 | July 1, 2024 | June 30, 2028 | RAMGOPAL, SRIRAM | reporter.nih.gov |
| Preventing avoidable deaths from pneumonia by improving use of intensive care | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $334,708 | August 7, 2018 | September 30, 2023 | VALLEY, THOMAS SEBASTIAN | reporter.nih.gov |
| Machine learning to predict cure in severe pneumonia episodes | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $332,834 | April 1, 2024 | March 31, 2029 | GAO, CATHERINE A. | reporter.nih.gov |
| Using Legionella-amoeba co-evolution to reveal new modes of immunity and pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $330,434 | July 1, 2020 | June 30, 2022 | LEVIN, TERA CATHERINE | reporter.nih.gov |
| Multidimensional analysis of the regulatory T cell response in children with severe viral pneumonia | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $326,160 | September 1, 2024 | August 31, 2029 | PRIGGE, ANDREW | reporter.nih.gov |
| Microbiome-based diagnosis of pneumonia in the acute respiratory distress syndrome | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $323,786 | January 22, 2018 | December 31, 2022 | KITSIOS, GEORGIOS | reporter.nih.gov |
| A novel Th17-enhancing adjuvant and conserved antigen for protection against viral/bacterial co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $308,669 | September 23, 2025 | March 31, 2027 | AKERLEY, BRIAN | reporter.nih.gov |
| Pulsed Focused Ultrasound (pFUS) exposures and devices for tissue permeabilization without contrast agents | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 | $306,746 | January 19, 2021 | September 18, 2021 | KHOKHLOVA, TATIANA | reporter.nih.gov |
| Nasopharyngeal Microbiome and Risk of Bacterial Pathogen Colonization in Infants | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $305,810 | May 23, 2018 | April 30, 2023 | KELLY, MATTHEW SCOTT | reporter.nih.gov |
| Respiratory infections and vaccination behaviors in patients with chronic inflammatory skin diseases | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2022 | $305,095 | July 1, 2019 | June 30, 2024 | NOE, MEGAN H | reporter.nih.gov |
| Type 3 secretion system inhibitors to treat Pseudomonas aeruginosa keratitis | NIH | National Eye Institute | 2022 | $300,156 | July 1, 2022 | June 30, 2023 | OPPERMAN, TIMOTHY J. | reporter.nih.gov |
| Inhibitors of T3SS translocon assembly to combat multi-drug resistant P. aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $300,000 | August 1, 2020 | May 31, 2024 | OPPERMAN, TIMOTHY J. | reporter.nih.gov |
| Treatment of Inflammatory Complications of Viral Pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $300,000 | June 20, 2022 | August 6, 2023 | AGRAWAL, ANDY | reporter.nih.gov |
| A comprehensive next generation sequencing diagnostic tool for lung infection among hospitalized patients | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $300,000 | August 11, 2022 | July 31, 2024 | FINGERLIN, TASHA E. | reporter.nih.gov |
| Novel antimicrobials in fighting carbapenem-resistant Klebsiella pneumoniae | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $300,000 | December 5, 2022 | November 30, 2024 | WU, REEN | reporter.nih.gov |
| Self-organizing synthetic human lungs on microchips to fight infection by RSV | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $300,000 | May 22, 2023 | April 30, 2024 | ETOC, FRED | reporter.nih.gov |
| Bacterial Pneumonia Therapeutic Antibody Safety Trial | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $297,917 | July 18, 2024 | November 30, 2025 | KAUVAR, LAWRENCE MICHAEL | reporter.nih.gov |
| Multivalent Adjuvant Immunization to Prevent Hospital Acquired Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $293,999 | February 10, 2020 | June 14, 2022 | SPELLBERG, BRAD J | reporter.nih.gov |
| Mechanism of Toxin Mediated Damage to the Lung Epithelium during S. pneumoniae Infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $293,000 | April 1, 2024 | March 31, 2028 | ADAMS, WALTER ISAIAH | reporter.nih.gov |
| Development of novel protein-based vaccine formulations to prevent pneumococcal colonization and disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $283,588 | September 17, 2020 | August 31, 2024 | GONZALEZ-JUARBE, NORBERTO | reporter.nih.gov |
| Lung epithelial cell reprogramming by CD4 T cells | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $270,692 | January 1, 2022 | March 31, 2023 | SHENOY, ANUKUL T | reporter.nih.gov |
| Elucidating regulatory control of Acinetobacter baumannii persistence and spread | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $270,000 | February 22, 2024 | January 31, 2027 | GREEN, ERIN REBECCA | reporter.nih.gov |
| Functional Genetic Analysis of Klebsiella pneumoniae Hypervirulence | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $268,720 | July 15, 2021 | August 31, 2023 | MIKE, LAURA ANZALDI | reporter.nih.gov |
| Randomized Controlled Trial of Macrolide Therapy for Mycoplasma pneumoniae | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $266,860 | July 1, 2023 | June 30, 2025 | AMBROGGIO, LILLIAM | reporter.nih.gov |
| Tobacco Mosaic Virus as a mucosal delivery platform for an intranasal vaccine against Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $261,846 | July 2, 2025 | June 30, 2027 | ARNABOLDI, PAUL MICHAEL | reporter.nih.gov |
| Development and implementation of a pediatric AI multi-modal digital stethoscope and respiratory surveillance system in South Africa | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2025 | $261,763 | September 4, 2025 | August 31, 2028 | MCCOLLUM, ERIC DOUGLASS | reporter.nih.gov |
| Novel Peptide Immunomodulators for Treating Sepsis | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $259,121 | May 3, 2023 | April 30, 2026 | AHMAD, SAIRA | reporter.nih.gov |
| The role of epigenetic regulator UHRF1 in stability of induced regulatory T-cell function during influenza A virus-induced lung injury | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $250,698 | March 1, 2023 | February 28, 2026 | JOUDI, ANTHONY | reporter.nih.gov |
| Developing a PIV5-based human metapneumovirus (HMPV) vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $249,999 | May 5, 2023 | October 31, 2024 | GINGERICH, MARIA CRISTINA | reporter.nih.gov |
| Defining macrophage defense during Klebsiella pneumoniae bacteremia | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $249,000 | June 11, 2025 | May 31, 2027 | HOLMES, CAITLYN LEIGH | reporter.nih.gov |
| Host immunity in the lung is determined by the enhanced utilization of glucose by multi-drug resistant Klebsiella pneumoniae | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $246,750 | January 1, 2024 | December 31, 2026 | AHN, DANIELLE | reporter.nih.gov |
| Mechanisms by Which Alcohol-Induced Dysbiosis Impairs Host Defense Against Klebsiella Pneumoniae | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 | $246,208 | September 20, 2019 | August 31, 2023 | SAMUELSON, DERRICK R | reporter.nih.gov |
| Novel mechanistic insights of inflammation and organ injury | NIH | National Heart, Lung, and Blood Institute | 2025 | $245,250 | September 1, 2025 | May 31, 2029 | JIN, YANG | reporter.nih.gov |
| Understanding the immunometabolic response to Klebsiella pneumonia infection | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $244,302 | April 1, 2022 | March 31, 2024 | WONG FOK LUNG, TANIA | reporter.nih.gov |
| A Point-of-Care Test for Rapid Diagnosis of Valley Fever | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $243,118 | July 24, 2023 | June 30, 2025 | GRILL, FRANCISCA | reporter.nih.gov |
| Impact of Regulatory T Cells on Host Susceptibility to Pseudomonas Aeruginosa Infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $239,348 | November 12, 2024 | October 31, 2026 | RIQUELME COLET, SEBASTIAN ALEJANDRO | reporter.nih.gov |
| Functions and Mechanisms of Lung Microfold cells during Invasive Pneumococcal Disease | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $237,897 | September 1, 2024 | July 31, 2026 | SURVE, MANALEE V | reporter.nih.gov |
| Identification of new or unrecognized virulence genes in hypervirulent Klebsiella pneumoniae and antivirulence genes in classical K. pneumoniae. | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $235,744 | August 19, 2020 | July 31, 2024 | RUSSO, THOMAS A | reporter.nih.gov |
| Determining how the giant Streptococcus Pneumoniae IgA1 protease cleaves its host IgA1 substrate and how this interaction can be blocked | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $233,250 | December 19, 2019 | November 30, 2022 | EISENMESSER, ELAN Z | reporter.nih.gov |
| Lung-innervating nociceptor sensory neurons suppresses Ly6chi monocyte responses to promote pneumonic sepsis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $228,000 | December 1, 2024 | November 30, 2026 | BARAL, PANKAJ | reporter.nih.gov |
| A vaccine specifically targeting T3SS-negative Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $227,250 | July 12, 2021 | June 30, 2022 | PICKING, WENDY L. | reporter.nih.gov |
| Oxidative killing of Pneumococcus | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $226,500 | March 1, 2020 | February 28, 2023 | RADA, BALAZS | reporter.nih.gov |
| Novel Mechanisms of CD4-Independent Immunity Against Pneumocystis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $226,500 | July 1, 2025 | June 30, 2027 | WRIGHT, TERRY W | reporter.nih.gov |
| Development of SupraGuard ETT, A Next Generation Composite Endotracheal Tube for the Prevention of Ventilator-Associated Pneumonia | NIH | National Heart, Lung, and Blood Institute | 2021 | $225,135 | September 15, 2021 | July 31, 2023 | VACHON, DAVID JOHN | reporter.nih.gov |
| Characterization of pneumococcal secretion chaperones required for virulence | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $224,638 | January 1, 2020 | December 31, 2022 | CAHOON, LATY ADRIELLA | reporter.nih.gov |
| Capsule protects intracellular pneumococci during vascular endothelial cell translocation | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $222,750 | March 1, 2020 | February 28, 2023 | ORIHUELA, CARLOS J | reporter.nih.gov |
| Sex Specific Regulation of B1 B Cell Self-Renewal and Natural Antibody Production | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $221,204 | September 1, 2023 | August 31, 2026 | WEBSTER, SARAH E | reporter.nih.gov |
| Genetically engineered macrophages to treat pulmonary infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $216,942 | February 6, 2020 | January 31, 2024 | WEST, TIMOTHY EOIN | reporter.nih.gov |
| Role of Prp protease in the S. pneumoniae ribosome | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $216,068 | November 8, 2024 | October 31, 2026 | DOKLAND, TERJE | reporter.nih.gov |
| Establishing Mechanisms of LOX-1-Dependent Immune Regulation During Pneumonia | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $212,754 | August 1, 2022 | July 16, 2024 | KORKMAZ, FILIZ | reporter.nih.gov |
| Investigating the relationship between antibiotics and nosocomial pneumonia. | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $211,875 | January 1, 2020 | December 31, 2022 | TORRES, VICTOR J. | reporter.nih.gov |
| Targeting Pneumococcal Colonization | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $211,875 | March 1, 2020 | February 28, 2023 | WEISER, JEFFREY NEAL | reporter.nih.gov |
| Utilization of the adjuvant effect of CRM197 protein to develop a trivalentprotein-vaccine against Streptococcus pneumoniae infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $211,500 | March 15, 2021 | February 28, 2022 | KHAN, NADEEM | reporter.nih.gov |
| Protective lung memory B cell functions and dynamics during respiratory infection | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $209,456 | June 1, 2021 | May 31, 2025 | ETESAMI, NEELOU | reporter.nih.gov |
| The Host Genetics of Age-Dependent Susceptibility | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $205,083 | July 1, 2020 | June 30, 2023 | MENACHERY, VINEET D | reporter.nih.gov |
| Age-dependent differences in the immune response to human metapneumovirus | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $203,115 | August 15, 2022 | August 14, 2027 | PARKS, OLIVIA | reporter.nih.gov |
| Interplay between respiratory syncytial virus and nucleotide biosynthesis pathways | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $199,384 | February 7, 2020 | January 31, 2023 | FEARNS, RACHEL | reporter.nih.gov |
| Genetic susceptibility to mucosal infections with aging (Resubmission) | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $199,375 | June 1, 2020 | May 31, 2023 | BOU GHANEM, ELSA | reporter.nih.gov |
| Extracellular matrix stiffness control of NLRP3 inflammasome activity | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $197,160 | July 1, 2025 | September 26, 2025 | OKIN, DANIEL | reporter.nih.gov |
| Training Program Plan to Improve Intervention Research for Prevention of Childhood Pneumonia in Guatemala | NIH | Fogarty International Center | 2022 to 2023 | $196,969 | August 15, 2022 | March 31, 2025 | CORDON-ROSALES, CELIA | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Northwestern University at Chicago | Chicago, IL | 24 | $34.7 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 18 | $21.2 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 6 | $19.1 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 14 | $17.6 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 18 | $17.5 million | 0 | $0 |
| Boston University Medical Campus | Boston, MA | 18 | $16.6 million | 0 | $0 |
| Washington University | Saint Louis, MO | 15 | $15.8 million | 0 | $0 |
| Ohio State University | Columbus, OH | 11 | $15.1 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 25 | $14.9 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 12 | $13.3 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 11 | $13 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 7 | $12.1 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 14 | $11.6 million | 0 | $0 |
| Stanford University | Stanford, CA | 6 | $10.8 million | 0 | $0 |
| SUNY at Buffalo | Amherst, NY | 10 | $10.6 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 17 | $10.2 million | 0 | $0 |
| Inhalon Biopharma, Inc. | Morrisville, NC | 5 | $9.8 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 6 | $9.5 million | 0 | $0 |
| Tulane University of Louisiana | New Orleans, LA | 7 | $8.9 million | 0 | $0 |
| University of Illinois at Chicago | Chicago, IL | 6 | $8.2 million | 0 | $0 |
| University of South Alabama | Mobile, AL | 10 | $7.8 million | 0 | $0 |
| University of Georgia Research Foundation Inc | Athens, GA | 7 | $7.5 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 6 | $7.4 million | 0 | $0 |
| Lurie Children's Hospital of Chicago | Chicago, IL | 6 | $7.2 million | 0 | $0 |
| University of Maryland Baltimore County | Baltimore, MD | 1 | $7.1 million | 0 | $0 |
| Tufts University Boston | Boston, MA | 5 | $7.1 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 6 | $7 million | 0 | $0 |
| ST. Jude Children's Research Hospital | Memphis, TN | 6 | $6.8 million | 0 | $0 |
| Arietis | Boston, MA | 2 | $6.6 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 5 | $6.6 million | 0 | $0 |
| Hackensack University Medical Center | Hackensack, NJ | 3 | $6.4 million | 0 | $0 |
| Nubad, LLC | Greer, SC | 2 | $6.2 million | 0 | $0 |
| Vaxnewmo, LLC | Saint Louis, MO | 4 | $6.2 million | 0 | $0 |
| Novobiotic Pharmaceuticals, LLC | Cambridge, MA | 1 | $6.2 million | 0 | $0 |
| Cedars-Sinai Medical Center | Los Angeles, CA | 3 | $6.1 million | 0 | $0 |
| Curza INC | Salt Lake City, UT | 3 | $5.9 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 6 | $5.9 million | 0 | $0 |
| Duke University | Durham, NC | 5 | $5.7 million | 0 | $0 |
| University of Texas Med BR Galveston | Galveston, TX | 5 | $5.7 million | 0 | $0 |
| Mucommune, LLC | Morrisville, NC | 3 | $4.9 million | 0 | $0 |
| University of Missouri-Columbia | Columbia, MO | 6 | $4.9 million | 0 | $0 |
| University of Washington | Seattle, WA | 10 | $4.7 million | 0 | $0 |
| University of Cincinnati | Cincinnati, OH | 7 | $4.7 million | 0 | $0 |
| University of TX MD Anderson Can CTR | Houston, TX | 2 | $4.5 million | 0 | $0 |
| University of Southern California | Los Angeles, CA | 3 | $4.5 million | 0 | $0 |
| Wake Forest University Health Sciences | Winston-Salem, NC | 6 | $4.5 million | 0 | $0 |
| Cleveland Clinic Lerner Com-Cwru | Cleveland, OH | 4 | $4.3 million | 0 | $0 |
| University of Texas HLTH Science Center | San Antonio, TX | 4 | $4.2 million | 0 | $0 |
| Rockefeller University | New York, NY | 2 | $4.2 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 6 | $4.2 million | 0 | $0 |
| Emory University | Atlanta, GA | 7 | $4.1 million | 0 | $0 |
| Lundquist Institute for Biomedical Innovation at Harbor-Ucla Medical Center | Torrance, CA | 2 | $4.1 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 4 | $4 million | 0 | $0 |
| University of Florida | Gainesville, FL | 4 | $4 million | 0 | $0 |
| University of Louisville | Louisville, KY | 5 | $3.7 million | 0 | $0 |
| Jackson Laboratory | Bar Harbor, ME | 1 | $3.5 million | 0 | $0 |
| Purdue University | West Lafayette, IN | 2 | $3.5 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 1 | $3.4 million | 0 | $0 |
| Florida State University | Tallahassee, FL | 2 | $3.4 million | 0 | $0 |
| Yale University | New Haven, CT | 7 | $3.3 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 3 | $3.3 million | 0 | $0 |
| La Jolla Institute for Immunology | La Jolla, CA | 2 | $3.3 million | 0 | $0 |
| Midwestern University | Downers Grove, IL | 2 | $3.2 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 4 | $3.1 million | 0 | $0 |
| Louisiana State University | Baton Rouge, LA | 4 | $3.1 million | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 3 | $3 million | 0 | $0 |
| Virginia Commonwealth University | Richmond, VA | 2 | $3 million | 0 | $0 |
| Northeastern University | Boston, MA | 1 | $3 million | 0 | $0 |
| Venatorx Pharmaceuticals, Inc. | Malvern, PA | 1 | $3 million | 0 | $0 |
| Medical University of South Carolina | Charleston, SC | 2 | $3 million | 0 | $0 |
| Sciogen, LLC | San Jose, CA | 1 | $3 million | 0 | $0 |
| Cincinnati Childrens Hosp Med CTR | Cincinnati, OH | 3 | $2.9 million | 0 | $0 |
| Brown University | Providence, RI | 1 | $2.8 million | 0 | $0 |
| Albany Medical College | Albany, NY | 1 | $2.8 million | 0 | $0 |
| Bluewillow Biologics, Inc. | Ann Arbor, MI | 1 | $2.6 million | 0 | $0 |
| Prokaryotics, Inc. | Union, NJ | 3 | $2.5 million | 0 | $0 |
| Western Michigan Univ School of Medicine | Kalamazoo, MI | 3 | $2.5 million | 0 | $0 |
| University of Iowa | Iowa City, IA | 3 | $2.5 million | 0 | $0 |
| University of Rochester | Rochester, NY | 2 | $2.4 million | 0 | $0 |
| Dartmouth College | Hanover, NH | 1 | $2.4 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 2 | $2.3 million | 0 | $0 |
| University of Kentucky | Lexington, KY | 3 | $2.3 million | 0 | $0 |
| Eldec Pharmaceuticals, Inc. | Durham, NC | 2 | $2.2 million | 0 | $0 |
| Research Inst of Fox Chase Can CTR | Philadelphia, PA | 1 | $2.2 million | 0 | $0 |
| University of Nebraska Medical Center | Omaha, NE | 3 | $2.2 million | 0 | $0 |
| Case Western Reserve University | Cleveland, OH | 2 | $2.1 million | 0 | $0 |
| Loyola University Chicago | Maywood, IL | 2 | $2 million | 0 | $0 |
| Cytoagents, Inc. | Pittsburgh, PA | 1 | $2 million | 0 | $0 |
| Pharmain Corporation | Bothell, WA | 1 | $2 million | 0 | $0 |
| Georgia Tech Research Corporation | Atlanta, GA | 2 | $1.9 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 3 | $1.8 million | 0 | $0 |
| University of North Dakota Main Campus | Grand Forks, ND | 4 | $1.8 million | 0 | $0 |
| Taxis Pharmaceuticals, Inc. | Monmouth Junction, NJ | 1 | $1.8 million | 0 | $0 |
| Abcombi Biosciences, Inc. | Amherst, NY | 1 | $1.8 million | 0 | $0 |
| University of Maryland, College Park | College Park, MD | 1 | $1.8 million | 0 | $0 |
| University of Mississippi Med CTR | Jackson, MS | 3 | $1.7 million | 0 | $0 |
| Carnegie Mellon University | Pittsburgh, PA | 2 | $1.6 million | 0 | $0 |
| Rochester General Hospital (ny) | Rochester, NY | 1 | $1.6 million | 0 | $0 |
| Arizona State University | Scottsdale, AZ | 1 | $1.5 million | 0 | $0 |
| University of Tennessee Health Sci CTR | Memphis, TN | 2 | $1.5 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 247 | $135,721,142 | 0 | $0 |
| 2024 | 267 | $135,829,779 | 0 | $0 |
| 2023 | 288 | $133,661,696 | 0 | $0 |
| 2022 | 268 | $120,255,862 | 0 | $0 |
| 2021 | 262 | $119,400,198 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Change of Recipient Organization (Type 7 Parent Clinical Trial Optional) | PA-24-254 | NIH | July 12, 2027 | Not listed | Notice number printed on 6 awards here | |
| Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed) | PA-24-182 | NIH | May 8, 2027 | Not listed | Notice number printed on 3 awards here | |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) | PA-24-176 | NIH | May 7, 2027 | Not listed | Notice number printed on 1 award here | |
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) | RFA-AI-27-002 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 333 awards here |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) | RFA-AI-27-005 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 333 awards here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.855 | November 16, 2026 | $50,000 | Same assistance listing 93.855 as 333 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 333 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 333 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.855 | January 7, 2027 | Not listed | Same assistance listing 93.855 as 333 awards here |
| HIV/AIDS Clinical Trials Network Leadership and Operations Centers | RFA-AI-28-001 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 333 awards here |
| HIV/AIDS Clinical Trials Network Laboratory Centers | RFA-AI-28-002 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 333 awards here |
| HIV/AIDS Clinical Trials Network Statistical and Data Management Centers | RFA-AI-28-003 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 333 awards here |
| HIV/AIDS Clinical Trials Network Clinical Trials Units | RFA-AI-28-004 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 333 awards here |
| Precision and Systems Biology to Uncover the Link Between Chronic and Infectious Diseases | RFA-AI-28-014 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 333 awards here |
| Immune Tolerance Network (UM1 Clinical Trial Required) | RFA-AI-28-005 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 333 awards here |
| Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed) | RFA-AI-28-012 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 333 awards here |
| Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) | RFA-AI-28-024 | NIH | 93.855 | February 11, 2027 | Not listed | Same assistance listing 93.855 as 333 awards here |
| NLM Institutional Grants for Research Training in Biomedical Informatics, Data Science, and AI (T15 Independent Clinical Trial Not Allowed) | RFA-LM-28-001 | NIH | 93.855 | February 11, 2027 | $775,000 | Same assistance listing 93.855 as 333 awards here |
| NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) | PA-27-100 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 333 awards here |
| NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) | PA-27-102 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 333 awards here |
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.